Statistical approaches to interim analysis : a critical appraisal by Floriani, Irene Claudia
Open Research Online
The Open University’s repository of research publications
and other research outputs
Statistical approaches to interim analysis : a critical
appraisal
Thesis
How to cite:
Floriani, Irene Claudia (2005). Statistical approaches to interim analysis : a critical appraisal. PhD thesis The
Open University.
For guidance on citations see FAQs.
c© Irene Claudia Floriani
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
rTill"Open University, UK
  Advanced School o f  Pharmacology----
Dean, h'nrieo Garattini M D
Mario Megri bistftute for
PfesfHiaeelegieiil Steseftreh
STATISTICAL APPROACHES TO INTERIM ANALYSIS: 
A CRITICAL APPRAISAL
Thesis submitted for the degree of Doctor of Philosophy 
at the Open University, UK
Discipline of Life Sciences
Irene Claudia Floriani, Degree in Biological Sciences 
Istituto di Ricerche Farmacologiche “Mario Negri” , Milan Italy
by
July, 2005
o k r r a  o p  ?><-*&t s i&t4;
(?Ate  o r  \ T
ProQuest Number: 13917280
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 13917280
Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
Abstract
Several important questions have been raised about decision of stopping a trial early 
and on what basis to reach such a decision. It seemed therefore of interest to investi­
gate the forms of monitoring used in cancer clinical trials and to gather information 
on the role of interim analyses in the data monitoring process of a clinical trial.
The project addressed the following issues:
- what is the performance of different interim analysis approaches;
- how often interim analyses are used in cancer clinical trials;
- which types of statistical analyses are more frequently adopted;
- how the data monitoring is organised and which is the weight of statistical 
analyses in the decisional process.
Analysis of performance of different statistical analysis approaches has been con­
ducted by comparing the probability of stopping and the estimation bias on clinical 
scenarios based on real data of trials performed in ovarian and colorectal cancers. 
The project also focused on the prevalence of different types of interim analyses and 
data monitoring for both safety and efficacy in cancer clinical trials.
Sources of investigation were the literature data and the protocols of cancer clinical 
trials included in the in the Italian registry of clinical trials.
A bstract iii
Results of our research indicate that the more widely used statistical approaches 
reduce the risk of “incorrect “ early stopping, compared with the adoption of no 
stopping rule, with similar performance. Analysis of protocols and early reports 
suggests that the implementation of these procedures in a monitoring strategy is not 
satisfactory. Use of interim analyses is still limited to the frequentist approach of the 
alpha-spending function, while the Bayesian is not considered.
Interim analysis plans are still scarcely described, even in more recent protocols, 
denoting a not yet sufficient attention to this issue not only by the researchers, but 
also by regulatory bodies.
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Summary
Several important questions have been raised about decision of stopping a trial early 
and on what basis to reach such a decision. Differences between treatments may 
be larger than expected or unanticipated adverse effects may occur, and either of 
these may justify early termination of a trial. Early stopping is sometimes suggested 
because continuing a trial would not provide sufficiently useful information to warrant 
continuation. Existing evidence from outside the trial, such as meta-analyses of 
data from comparable trials, other existing evidence external to the trial itself and 
the nature of the condition and its alternative treatments may be also taken into 
consideration when deciding to stop or continue a trial.
Since data from the trial may later constitute the base of management of future 
patients, the evidence should also be sufficiently convincing to the wider clinical and 
patient communities to determine future practice.
In chronic life-threatening diseases, like cancer, evidence of early therapeutic bene­
fits may be even more compelling than in other diseases and the detection of the best 
trade-off between obtaining results as earlier as possible and getting good estimation 
of the magnitude of treatment effect is particularly important.
A range of formal statistical approaches can be used as a basis for judging at 
what point such differences are so extreme as to be sufficiently unlikely to reflect 
the play of chance. These analyses help to control for errors in decision making and 
estimation; however, although interim analysis approaches in clinical trials are widely
Summary xviii
known, information on explicit adoption of some form of planned monitoring, even in 
long-term trials, is still scarce and basically driven by the published reports of studies, 
which rarely include details on the strategies for data monitoring and interim analysis 
plan. More research is needed looking at actual protocols on ongoing studies.
It seemed therefore of interest to investigate the forms of monitoring used in cancer 
clinical trials and in particular to gather information on the role of interim analyses 
in the data monitoring process of a clinical trial.
More specifically, the project addressed the following issues:
- what is the performance of different interim analysis approaches;
- how often interim analyses are used in cancer clinical trials;
- which types of statistical analyses are more frequently adopted;
- how the data monitoring is organised and which is the weight of statistical 
analyses in the decisional process.
Analysis of performance of different statistical analysis approaches has been con­
ducted by comparing the probability of stopping and the estimation bias on clinical 
scenarios based on real data of trials performed in ovarian and colorectal cancers.
The project also focused on the prevalence of different types of interim analyses 
and data monitoring for both safety and efficacy in cancer clinical trials. Source of 
investigation was the literature data and the protocols of cancer clinical trials included 
in the Italian registry of clinical trials.
The reason for using a protocol registry is that the quality of published reports is 
generally not sufficiently high and details of statistical analysis are seldom reported. 
Moreover, even when reported, statistical analysis of published trials belongs to pro­
tocols designed years before the study publication, and may not be appropriate for
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estimating the up to date prevalence of utilisation and kind of interim analyses. Ita­
lian registry of clinical trials gave an unique opportunity to get this information and 
allow a critical appraisal of the statistical designs utilized in current cancer clinical 
trials.
Similar data have been retrieved from the clinical studies published between 2000 
and 2005 in order to compare older strategies to the more recent approaches. The 
impact of results of interim analyses on the decision of modifying the planned study 
conduction has been investigated in two separated ways: first, to provide information 
on how often an early termination of a trial is caused by results of an interim analysis. 
For this proposal, causes of early interruption have been explored searching published 
papers of preliminary or early clinical trial results. Second, to obtain information 
from the literature on the modalities of implementation of interim analyses in the 
data monitoring process, by investigating which are the more reported forms and 
rules for data monitoring.
The most important findings of our research can be summarised as follows:
- The more widely used statistical approaches reduce the risk of “incorrect” early 
stopping, compared with the adoption of no stopping rule. Performance of 
restricted procedures and alpha-spending function with O’Brien and Fleming 
boundaries are very similar, while triangular test obtains values that are similar 
to what achieved using Bayesian approach;
- If no approach is used, the probability of interrupting at early stages increases, 
with a higher probability of incurring an estimation bias. Since stabilization 
of the estimates appears to happen when a substantial amount of events has 
occurred, it seems appropriate to conduct interim analyses only after a t least 
half of the expected events occurred, in order to reduce bias. W ith respect to 
this, alpha-spending function with O’Brien and Fleming approach and restricted
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procedure, which are more protective against early termination at the beginning 
of the study, favour a reduction of the magnitude of estimation bias;
- The number of analyses has a moderate impact on estimation, when some 
approach is adopted, but it can be important when no criteria for making 
allowance for multiple analyses are used.
Analysis of protocols and early reports suggests that, although the field of metho­
dology of interim analyses of clinical trials is largely covered and various approaches 
are available, the implementation of these procedures in a monitoring strategy is still 
uncommon.
According to the sources of data investigated, analysis of statistical aspects of ran­
domised clinical trial protocols in oncology, systematically collected in the National 
Monitoring Centre for Clinical Trials, reveals tha t the most recent trend, based on the 
analysis of the international and national trials with participation of Italian centres, 
is still not completely satisfactory.
The most important figures derived by this project indicate that only sixty-four 
percent of the protocols incorporate statistical interim analysis plans. Despite of the 
large availability of statistical methods for interim analysis, the almost only used 
approach is the frequentist method, with O’Brien and Fleming boundaries. A data 
and safety monitoring committee is present in 58% of protocols, but there is lack of 
information on their composition and on rules to be implemented.
When looking at the data derived from early reports, the adoption of a formal 
process of interim analysis affects only a minority (13%) of published trials and 
slightly more than half (55%) of early publications based on interim analysis. Again, 
the largely preferred approach is the frequentist method, generally with O’Brien and 
Fleming boundaries. Explicit use of a data and safety monitoring committee is re­
ported only in 20% of reports of early publications explicitly based on interim analysis,
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and the lack of information regarding its rules and composition is confirmed.
The most important ’take-home’ message is that interim analyses play a fun­
damental role in the balance between the need of timely information regarding the 
treatment effect and the control of false positive errors and estimation biases. The 
most discussed and popular approaches appear to have good performance. However, 
the use of interim analyses is still limited basically to the frequentist approach of 
the alpha-spending function, while the Bayesian is not considered at all. Moreover, 
interim analysis plans are still scarcely described, even in more recent protocols, de­
noting a not yet sufficient attention to this issue not only by the researchers, but also 
by regulatory bodies.
Chapter 1
Introduction
1.1 Issues in m onitoring clinical trials
The simplest approach for evaluating results of a clinical trial is to plan only one 
statistical analysis at the end of the study, using a fixed-sample size design: planning 
and conduction are easy, and correct methods for estimation are available.
This approach, natural when all observations are available in a short period of 
time, is less appropriate when data become available sequentially. This is the case of 
studies on chronic diseases, like cancer, in which recruitment may last many years, 
so that the first outcomes can be observed when the accrual is still ongoing: in such 
situations there might be ethical, practical and economical reasons for looking at the 
data before the planned end of the study.
Data monitoring conducted during a still ongoing study focuses on the following 
issues:
- Performance;
- Data integrity;
- Safety;
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- Treatment effect.
The assessment of study performance in terms of quality of data, protocol adhe­
rence, recruitment rate is normally performed periodically by the study sponsor in 
an informal way, adopting modalities which can be grouped under the definition of 
“internal monitoring” (Armitage, 1991).
On the contrary, tasks of external monitoring are to evaluate data integrity, safety 
and efficacy of treatment and to provide advice on continuing the study as originally 
planned, on suggesting changes in the conduction, or on stopping the study.
The advice is mainly based on trial results, but should take into account the 
context of information currently available at the moment of the analysis.
This process, named “interim analysis” is usually conducted by a data and safety 
monitoring committee (DSMC), composed by a group of experts in the involved 
fields (biostatistician, clinical researcher, epidemiologist, clinician with expertise in 
the disease under investigation). The committee should be preferably independent, 
in the sense that people taking part on it have no involved interests in the study and 
do not directly participate in the trial.
Undoubtedly, ethical reasons play a major role on decision to stop a trial, since one 
should minimise the number of subjects treated with an unsafe, uneffective or clearly 
inferior treatment: in this sense interim analyses make the process more efficient. 
The increase in efficiency has repercussion also on economic side, since in case of 
early stopping, the study size and duration are obviously shortened. Another goal 
is to make available a beneficial treatment as soon as possible. A further positive 
role of interim analyses is that they may increase interest among study participants, 
sometimes revitalising the accrual and study participation.
However, there are also disadvantages in conducting an interim analysis, thus 
influencing study conduction: immature results may provide imprecise or even biased 
point and interval estimates of the treatment effect, increasing the error in infe­
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rential process (Hughes and Pocock, 1988). In fact, when a clinical trial is closed 
because a treatment difference has been detected, the estimate of the magnitude of 
that difference will overstate the “true” value (Armitage et al., 1969). Finally, it is 
important to emphasize that trials stopped early are likely to be of small size, and 
as a consequence their results may lack of both statistical precision and credibility, 
since medical community might give them a sceptical welcome, even in case of highly 
significant results.
Therefore, while informal reviews are necessary, the process of repeatedly evalua­
ting data must be done with caution, especially early in the course of a trial when the 
number of both participants and events related to safety and efficacy are relatively 
small.
All sequential designs have some common features. First, they relate patient 
accrual (or occurred events) to when analyses are performed. Then, they define 
a statistic to test the null hypothesis, as well as a statistical stopping rule, which 
specifies at each interim analysis the difference between groups that will result in 
stopping the study. Even so, it should be stressed that the decision to stop a trial 
before the pre-specified final analysis should not be guided only by statistical, but 
also by practical (toxicity, ease of administration, costs, etc.), as well as clinical 
considerations: for this reason it is prefereable to refer to them as guidelines, rather 
than rules.
There is no simple formula for how often data should be retrieved: monitoring 
activities should be commensurate with the nature, size, and complexity of the trial. 
Therefore whereas generally for phase I and early phase II trials a DSMC may not be 
appropriate due to the small size and short duration of these studies, in late phase II, 
phase III and phase IV trials more frequent and rigorous looks at the data become 
necessary.
A monitoring plan should also consider the severity of the disease, the nature of
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the intervention, and the characteristics of the target population.
All of these factors need to be taken into account in deciding on the frequency 
and intensity of the activities.
1.2 Summary of statistical m ethods for interim  
analyses
Many quantitative methods have been developed to monitor the proceeding of ran­
domized clinical studies, even if since the beginning of its development the theory 
of the sequential analysis has been the waterfront of debates between Bayesian and 
frequentist statisticians (Barnard, 1949; Anscombe, 1963; Birnbaum, 1964; Armitage, 
1963, 1967; Cornfield, 1966a, 1966b; Dupont, 1983; Brown, 1983; Canner, 1983), also 
because in this field the differences between frequentist and Bayesian approaches are 
particularly evident.
The main matter of controversy is if the knowledge of the previously carried out 
or planned for the future analyses should somehow influence the approach to the 
analysis of the data.
Frequentists, who follow the principle of the repeated sampling, support the ne­
cessity of adjustment in the analysis phase to make allowance for the multiple tests 
carried out.
On the other side, Bayesan statisticians, who are “supporters” of the principle 
of likelihood (Berger, 1985; Berry, 1987) consider that the inference should only be 
based on the function of likelihood and that the design has no role in the analysis. 
They underline that, unlike frequentist, Bayesian inference adhers to the likelihood 
principle, according to which all information contained in the data relevant to hy­
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pothesis testing, is captured by the ratio of the likelihoods under those hypotheses, 
and that inference not based on this ratio is not as relevant.
Surely the process of trial monitoring involves rules often complex and subjective, 
based on both statistical and non statistical aspects. Furthemore, none of the pro­
posed monitoring methods seems optimal in every different circumstances and since 
they have been developed to solve specific issues, some aspects of the problem seem 
better solved by some approaches and some other aspects by other approaches.
W ith no doubt in the practice frequentist approaches are the most widely used, 
even if in theory there are no reasons to prefer them to Bayesian.
Statistical monitoring methods can be classified according to two factors (Freed­
man et al., 1994):
- whether the method is frequentist or Bayesian;
- whether the method uses the current evidence, available at the moment of the 
analysis or data predicted by supposing for the future observations a certain 
trend until the achievement of the planned sample size.
Current frequentist approaches include fully sequential and group sequential me­
thods, alpha-spending functions, and repeated confidence intervals, whereas stocha­
stic curtailment is a frequentist method that uses predictions. Bayesian counterparts 
are based on either the posterior or the predictive distributions.
Among current and predictive methods, Armitage (1989), as well as Freedman et 
al (1994), suggested to use “current” ones, since they are based on real data and 
not on the projection of what is anticipated but has not yet occurred. Regardless the 
specific method used, a key issue to keep in mind is that statistical rules are only a 
side of the question, all the more so because they tend to oversimplify the information 
relevant to the decision to take and the way it is taken through.
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Comprehensive reviews of statistical aspects of monitoring can be found in White­
head (1992), Jennison and Turnbull (1990) and Piantadosi (1997).
1.2.1 General statistical aspects
We will consider the case of trials aimed at comparing the efficacy, in terms of pro­
longed survival, of an experimental treatment with a control (represented by the 
reference standard or no treatment), testing the null hypothesis of no treatment dif­
ference, against an alternative hypothesis tha t the effect of the treatments differs, 
namely that one is greater than the other.
Let 9 be the natural logarithm of the unknown parameter of interest, the hazard 
ratio (HR), measuring the relative difference in efficacy between treatments:
assumed to be constant over all t, where he and hc are the hazard functions in the 
experimental and control group, respectively. It represents the limiting probability 
that the event (assumed to be undesirable) occurs at time t, conditional on it not 
occurring before t.
The proportional hazards model under which he(t) = e°hc(t) for all t  is being 
assumed.
Values of 6 lower than zero represent an advantage for the experimental treatment, 
values greater than zero an advantage for the control treatment, whereas the value 
zero evidence in neither directions. 6r denotes the difference considered of clinical 
interest (reference improvement) between the two treatments.
An equivalent form to (1.1) is:
( i . i )
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=  In
In Se(t) 
In Sc(t)
(1.2)
where S e and Sc are the survivor functions in the experimental and control group, 
respectively, representing the probability that the event occurs after time t.
The hypotheses to be tested are:
Hq : 9 = 0 versus Hi : 6 ^  0 (1.3)
Two sample statistics can be used in the investigation of 6 (Piantadosi, 1997): the 
first, denoted by Z*, is a cumulative measure of the observed difference between treat­
ments. For survival data it is called the logrank, equal to the observed number of 
events in the experimental group minus the expected number under the null hypoth­
esis. The second, denoted by V, measures the amount of information contained in 
Z* about 6. It is approximately equal to one quarter of the total number of observed 
events, thus increasing as the trial progresses. When 9 is small and study sample of 
moderate or large size, then Z* is approximately normally distributed with mean 6V 
and variance V. Z * can be also used as test statistic and the test based on it is called 
the logrank test: Z*2/ V  is calculated and then referred to a x 2 distribution on one 
degree of freedom (df). Z* is negative if the experimental treatment is better than 
control, otherwise is positive.
In order to facilitate the presentation of results, from now then Z  — — Z* will be 
used. Therefore, Z is positive if the experimental treatment is better than control, 
otherwise Z is negative.
- If Z  > k, with k =  (a, /3), then the null hypothesis will be rejected at the level 
of significance a  and it will be concluded that the experimental treatm ent is
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superior to the control;
- I f  Z  < —k, then the null hypothesis will be rejected concluding tha t the expe­
rimental treatment is inferior.
The requirements for the test are thus:
P ( Z > k ;  0) =  |  and P{Z  > k-,0R) = 1 -  /? (1.4)
where the term appearing within the brackets after the semicolon represents the true 
value of 9.
When 9 = 0, Z is normally distributed with mean 0 and variance V. When 0 = Or , 
Z is normally distributed with mean Or V  and variance V.
The requirements (1.4) are satisfied by a suitable choice of V and k, namely:
V  = Va/2 +  'Qp and k = (r)a/2 + r)p)r]a,2 
Qr
(1.5)
where t;7 denotes the upper 100(1-7 ) percentage point of the normal distribution for 
any value of 7  between 0 and 1.
The information required increases as the reference improvement decreases, as the 
working significance level decreases, and the power increases.
At each analysis, the actual value of V observed should be used. As Z is ap­
proximately normally distributed with mean 0V and variance V, 9 = Z f V  provides 
a simple estimate of 9. When sample are large, 9 is approximately equal to the 
maximum likelihood estimate of 9 and (Z/V-I.OO/a/K, Z/V+I.OO/a/F) provides an 
approximate 95% confidence interval (Cl) for 9.
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1.2.2 Frequentist approach
Frequentist sequential procedures are of two types: those derived from the boundary 
approach and those derived from the repeated significance test approach.
In the first approach the two statistics Z and V, described in section 1.2.1, are 
plotted one against the other and at each analysis the identified point is compared 
to a prefixed stopping boundary; in the other a certain number of interim analyses 
are performed with significance levels adjusted to make allowance for repetition.
Earlier designs implied frequent looks of the data, even at each new available ob­
servation, so that the monitoring could be considered as continuous. This is rarely 
feasible due to practical problems, thus later designs, the so called “group sequential 
trials” , tried to solve this gap by involving a fewer number of analyses and for their 
easier conduction they are of common use.
1.2.2.1 Boundary approach
According to this approach, at the 2-th inspection, Zi and Vi are calculated, as well 
as an upper Ui and a lower stopping limits, (li < U{).
- If Zi > Ui then the trial will be interrupted, with the rejection of the null hy­
pothesis and the conclusion that experimental treatment is better than control;
- If Zi < li again the trial will be stopped with either the rejection of the null 
hypothesis and the conclusion that the experimental treatm ent is worse than 
the control, or the acceptance of the null hypothesis and concluding that there 
is no evidence of any difference;
- If li < Zi < Ui then the study will continue until the next look.
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If a boundary has not been crossed, the process will continue endlessly (open 
design), or up to a pre-specified maximum number of enrolled patients (or events 
occurred). It is not necessary to define in advance the timing of the analyses, as well 
as the amount of new information between analyses is not required to be of constant 
size. Accordingly, the values of V*, Ui and l{ have not to be fixed in advance, too. 
On the contrary, the identification of a prespecified rule for the calculation is very 
important. As a general principle, Ui and li are determined as a function of Vi , . . .  Vi, 
but they must have no relationship with Z i , . . .  Zi.
Due to the previously mentioned difficulties in following continuous monitoring, 
a certain form of adjustment should be introduced to account for the discrete way 
of monitoring, which makes more difficult to detect the crossing of the boundaries. 
This can be done by bringing boundaries nearer, yielding a “Christmas tree” shape.
Sequential designs were introduced for the first time in the context of industrial 
quality control at the end of twenties of the last century (Dodge and Romig, 1929). In 
such experiments, the components are classified as effective or defective and a batch 
is accepted only if its proportion of defectives is acceptably low. These procedures 
were drew on and developed during II World War in connection with military quality 
control in the same time and in a similar way by Wald in the United States and by 
Barnard in England. Considered military secrets, these methods were widespread 
only after the end of the war, disguised as a book (Wald, 1947) and as an address to 
the Royal Statistical Society (Barnard, 1946).
Particularly the work of Wald was of considerable speculative impact on clinical 
research, even if of limited practical application, since addressed toward sampling in­
spection more than comparative trials. We owe to the same author the development 
of sequential stopping rules and of the Sequential Probability Ratio Test (SPRT) for 
testing between to simple hypotheses:
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Ho : 9 = 6\ versus Hi : 6 — 02 (1.6)
Suppose that based on the test result, one out of two decisions, Do or D\ is taken, 
the first favouring Ho, the second favouring Hi, with a  and (5 the probabilities of the 
errors made choosing D\ when Ho is true or D0 when Hi is true.
According to Wald’s method, at the occurrence of each event the ratio L i / L q of 
the likelihoods of Hi and Ho is calculated. The study is closed with the decision Di 
if at any stage:
Li > l - l  
L 0 ~  a
or with the decision Do if
Li < (3
Lo ~  1 — a ’
otherwise the study is continued.
These values, expressed through the likelihood ratio, are constant during all study 
period and correspond to those that should have been obtained using a fixed-sample 
design. This approach leads to open plans and in the simpler cases to graphical 
methods with linear boundaries. The actual error probabilities are only approxi­
mately equal to the specified values, since it is easier that the likelihood ratio value 
crosses one boundary rather than taking exactly the same value. Solutions for cal­
culating exact probabilities have been supplied by many authors (Barraclough and 
Page, 1959; Manley, 1970; Dhuang-Zhen, 1990). Various forms of open designs have 
been described by Armitage (1954, 1975).
(1.8)
(1.7)
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In Figure 1.1 the open SPRT in the case of continuous monitoring is showed. The 
plot of Z against V, called the “sample path” is updated at each inspection of the 
data. If it crosses the green line, the null hypothesis is rejected concluding that the 
experimental treatment is superior, whereas if the red line is crossed, again H0 is 
rejected and the conclusion is tha t control treatm ent is superior. Blue line crossing 
causes on the contrary the acceptance of the null hypothesis. These colours will be 
used with the same meaning through all this chapter.
Z
0
Figure 1.1: O pen sequential probability ratio test
Theoretically, several reasons make the open SPRT designs appealing for con­
structing stopping rules for study monitoring. First they are based on the likelihood 
function, an efficient summary measure, second they are easy to use and interpret 
and third allow to continuously monitor accumulating data (Piantadosi, 1997).
In practice, such intensive surveillance and prompt action are rarely feasible: it 
is often more reliable to analyze data at periodic intervals, say every few months.
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Furthermore, the plan is open, i.e. there is the chance that a boundary will never be 
crossed and the study will not have an end.
A possibility of solving this latter problem is to define a maximum number of 
patients (or events): once reached, the study is interrupted either with evidence in 
neither direction or with the conservative approach of accepting the null hypothesis. 
Otherwise, it is also possible to adopt a close design, truncated at certain point, as 
shown in Figure 1.2 in which we are sure to cross a stopping boundary.
Z
0
Figure 1.2: R estricted  sequential probability ratio test
The application of sequential methods to clinical studies was first attem pted by 
Kilpatrick and Oldham (1954), Bross (1952, 1958) and Armitage (1957).
Bross was escribed to suggest the use of two plans, deliberately closed and there­
fore distinct from arbitrarily truncated open plans.
Restricted procedures, shown in Figure 1.3 and introducted by Armitage (1957), 
are similar to Bross’ design, even if they provide a much wider choice. Such a design
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offers scarce chances to early interrupt the study and in this sense it does not always 
satisfy the ethical requirements of early detecting an important difference in efficacy 
between treatments.
Other sequential designs are the triangular, the reverse triangular and double 
triangular tests (Whitehead, 1983, 1992; Whitehead and Stratton, 1983), tha t as 
well as the restricted procedure are special cases of the modified sequential probability 
ratio test introduced by Anderson (1960). The way to reach a conclusion is the same 
of tha t presented for the open SPRT.
Figure 1.3: R estricted  procedure
The triangular test, shown in Figure 1.4, has convergent boundaries, giving an 
asymmetrical triangular continuation region, which is finite. The study is continued 
until the sample path stays within the two boundaries and is stopped when one of 
the boundaries is crossed. The conclusion of the study depends on which boundary
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is crossed: experimental better than control for upper boundary, experimental non 
different or inferior to control for the lower boundary.
The reverse triangular test, shown in Figure 1.5 is particularly suitable for non­
inferiority trials, in which even if the expected efficacy of the experimental treatment 
is equivalent or a little lower than the control one, it holds some known advantages 
in other endpoints (tolerability, costs, feasibility). In such a situation, we are not 
interested in distinguishing between superiority and equivalence, since in either case 
there is a benefit in using the new treatment: therefore this design has a high power 
to detect inferiority of the experimental treatment and a lower power to detect its 
superiority.
Figure 1.4: Triangular test
A double triangular test combines a triangular test and a reverse triangular test. 
In most cases this symmetric design, tha t guarantees a high probability of detec-
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Figure 1.5: R everse triangular test
ting either superiority or inferiority of the experimental treatment, leads to the same 
conclusions of the triangular test. The only difference is that when the sample path 
crosses either the lower or the upper broken line, the triangular test would stop imme­
diately the study, while the double triangular test would continue in order to decide 
whether experimental treatment is not different or worse/better than the control 
treatment. The design of the double triangular test is reported in Figure 1.6.
1.2.2.2 R epeated  significance testin g  procedures
From a clinical point of view, the optimal design is one tha t allows to point out a 
difference between treatments as soon as it reveales itself with an acceptable grade 
of certainty: this can be achieved with frequent analyses of data as they become 
available.
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Figure 1.6: D ouble triangular test
The gap is that repeated use of significance tests on accumulating data increases 
the overall significance level, that is the probability of having at least one statistically 
significant difference, even when the hypothesis of no treatment difference is true. The 
greater the number of looks, the greater the possibility of observing a false positive 
result.
This phenomenon is called “optional stopping” , because it was showed by Feller 
(1940) as a possible explanation of particularly favourable results in experiments on 
extra-sensory perception.
Previously, Kintchine (1924) underlined that by repeated analyses of accumula­
ting data one can be absolutely sure to obtain an extremely low level of nominal 
significance, i.e. p < 0 .000001 , even under the null hypothesis.
The same concept, couched also by Cornfield (1966b), who the term “sampling 
versus a foregone conclusion” is due to, is extremely important in the decision process, 
since if we are certain to achieve any level of nominal significance even when the null
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hypothesis is true, we cannot rely on even highly significant results obtained. Robbins 
(1952) and Anscombe (1954) provided further discussion on this point.
Armitage et al. (1969) were the first to quantify the extent to which the type I 
error probability is increased over its nominal level, if a standard hypothesis test is 
conducted in a series of interim analyses. They studied the case of testing a normal 
mean with known variance and set the significance level at 5%. As an example, if a 
total of two analyses (one interim and one final) are performed the error is inflated to 
8%. If a total of five analyses (four interim and one final) are performed this figure 
is 14%.
Many authors investigated the problem of “optional stopping” for different di­
stributional forms of the endpoint variable (Armitage et al., 1969; Armitage, 1971; 
McPherson, 1974) and in particular for survival data (Canner, 1977). These calcula­
tions have been also done when the alternative hypothesis is true, therefore focusing 
on the power of clinical trials providing for interim analyses of the data (McPherson 
and Armitage, 1971). It is interesting to note that apart from the distributional form 
of the response variable, if the analyses are performed at equally spaced intervals the 
frequency properties of repeated significance tests are extremely similar.
A possibility of controlling the probability of type I error is to adopt at each 
analysis a more stringent nominal significant level, thus keeping the overall alpha 
error at some suitable level (usually 5%). Since more and more conservative nominal 
significant levels must be adopted as the number of looks increases, this implies that 
planning in advance the maximum number, N, and the frequency of interim analyses 
becomes not only worthwile, but also necessary in order to apply a valid repeated 
significance testing procedure.
At the ith inspection, Z{ and V{ are calculated, and the observed fixed-sample 
significant level compared with r]i, called the nominal significance level. Using the 
approximate normal distribution of Zi the possibilities are:
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- li < Zi < Ui for i = 1 . . .  N  — 1 =$> the study continues;
- li < Zi < Ui for i = N  ==> the study closed, with evidence in neither direction;
- Zi > Ui for i = 1 . . .  N  ==> the study is interrupted, concluding tha t the expe­
rimental treatment is superior to control;
- Zi < li for i = 1 . . .  N  =>• the study is interrupted, concluding tha t the expe­
rimental treatment is inferior to control
where
li — ki \ /  hi i Ui — ki"\/Vi (1.9)
and ki is the 100(1 — \r]i) percentage point of the standard normal distribution. 
As already underlined, the values of r]i. . . ,  7}n  are chosen to maintain the overall 
significance level equal to a.
Repeated significance testing were introduced by Armitage (1958) and extensively 
explained by the same author (1975).
Earlier designs imply equally spaced inspections in terms of information available, 
Vi = iVI, i =  1 , . . . ,  N  and therefore equal nominal significance levels r]i = rf, i =  
1, . . . ,  N  and ki =  k, i = 1, . . . ,  N.  The number of inspections can be high, even after 
every individual patient or pair of patients.
Group sequential approaches were proposed for the first time by Cutler et al. 
(1966), followed by McPherson (1974, 1977) and Pocock (1977, 1982) as a reasonable 
compromise between fully sequential and fixed-sample designs, in which plans are 
made for a small number of interim analyses, in contrast to fully sequential methods 
in which analyses are performed after the recording of even each outcome.
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This alternative method is motivated partly because a little additional increase 
in efficiency is added by undertaking more than five analyses during the course of 
a clinical study, unless an extremely large treatment difference may be anticipated 
(Pocock, 1982) and because data management constraints usually do not allow for 
the continual availability of good quality data.
Many sequential stopping boundaries have been proposed to guide early stopping 
of clinical studies.
Pocock (1977) used a constant nominal level for all analyses.
O’Brien and Fleming (OBF)(1979) proposed for equally spaced analyses a signi­
ficance level so that ki =  ki/y/i, i = 1, • • •, AT. Since for equal spacing, Vi — iVi, from 
equation (1.9) the boundaries are li = —ki/Vi  and Ui = k \/V \  . The graphic of Zi 
against Vi is compared with a constant horizontal line, as for the restricted procedure 
with horizontal boundaries.
W ith a = 0.05 and a total number of five analyses, Pocock procedure uses significant 
levels 771,...,775 — 0.0158, while that of O’Brien and Fleming 771 =  0.00001,772 =  
0.0013,77s -  0.0084,774 -  0.0225,775 -  0.041.
Pocock approach was criticized, since offers high probability of early stopping, 
causing lack of accuracy in estimation of treatment effect. Another problem is th a t it 
undertakes the last analysis at a p-value considerably smaller than the conventional 
value of 0.05 (Geller and Pocock, 1987).
OBF method was the first attempt to overcome the above mentioned problems, 
with tests of gradually decreasing stringency, even if it offers little chance of early 
stopping and it is perhaps too conservative at the first analyses: for this reason the 
same authors suggested a little change of their design (Fleming et al., 1984). This 
approach in case of time to event data preserves the sensitivity to late occurrence of 
survival difference.
Pocock (1982) suggested intermediate schemes between these two extremes, tha t
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minimize the sample size in order to detect the alternative hypothesis with a certain 
power.
Even more conservative requirements were suggested by Haybittle (1971) and Peto 
et al. (1976). According to what proposed by the first author, the study is stopped 
if the chi-square statistic on one degree of freedom is greater than nine at an interim 
look or greater than 3.84 at the final analysis.
More particularly, if aq = a 2 . . .  otN-i ~  0.0027, it is possible to maintain cxn = 
0.05 and the overall type I error of about 0.05.
Peto suggested a similar way to proceed: it is very simple (p <  0.001 for stopping 
the study early) and can be appropriate when there is the need of having some 
flexibility in analysis timing.
Other group sequential families have been proposed by Koepcke et al. (1982), 
Wang and Tsiatis (1987) and Pampallona and Tsiatis (1994). Armitage (1975) and 
Jones and Whitehead (1979) suggested .that continuous sequential boundaries could 
be applied to the logrank statistic by plotting the logrank score against the Mantel- 
Haenszel variance.
Gail et al. (1981) showed throughout simulations that the group sequential boun­
daries proposed by Pocock and O’Brien and Fleming could be used with the logrank 
test, provided the logrank test was performed after successive equal numbers of events.
Sellke and Siegmund (1983) presented asymptotic arguments which imply tha t 
group sequential boundaries have appropriate size under the null hypothesis, when 
the logrank test is performed at intervals defined by equal number of events.
Slud (1984) has shown that sequentially computed logrank tests have uncorrelated 
increments for various follow-up patterns.
Tsiatis (1981, 1982) demonstrated that logrank increments are asymptotically 
normal and independent, under the null hypothesis.
DeMets and Gail (1985) showed that boundaries of Pocock, O’Brien and Fleming
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and Haybittle are still valid, even if the analyses are performed at equal intervals 
of time instead of events. They are robust also when different test statistics, whose 
distribution in large samples is approximately normal, are used (Geller and Pocock, 
1987).
DeMets and Ware (1980) proposed one-sided group sequential tests. They con­
sidered two methods, modifications of repeated significance testing procedures and a 
third derived from the SPRT of Wald.
In a following paper, DeMets and Ware (1982) produced tests with more stringent 
requirements for stopping early, based on the two-sided test of O’Brien and Fleming. 
A common feature of these designs is the lack of simmetry, that give rise to additional 
parameters in the boundaries and apparently to a certain grade of arbitrariness in 
the choice of the tests.
One-sided tests can be also derived through the approach of repeated confidence 
intervals (Jennison and Turnbull, 1989), described in section 1.2.2.5.
Gould (1983) noticed that for not life-threatening diseases, early interruptions due 
to extremely negative results are appropriate, but if interim results suggest an advan­
tage for the experimental treatment the study should be continued till the planned 
end, in order to provide adequate informations about secondary endpoints, and/or 
safety, and/or sub-groups of patients. Similarly, if safety is the primary endpoint, the 
study should be interrupted only in case of negative results.
Jennison (1987) for constant size groups and a fixed number of analyses derived 
tests that minimize a target function in order to detect the optimal region of conti­
nuation.
Emerson and Fleming (1989) developed a family with one parameter symmetrical 
designs, whose boundaries are almost totally efficient when compared with the opti­
mal test of Jennison.
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1.2.2.3 A lpha-spending functions
Group sequential approaches require number and timing of interim analyses to be 
specified in advance and this may represent a difficulty in their application. For 
example, if the study duration is longer than what planned due to a lower accrual 
rate, the number of annual interim analyses should consequently be changed.
Lan and DeMets (1983), Lan et et al (1989a, 1989b) proposed a more flexible 
implementation of the group sequential boundaries through an “alpha-spending func­
tion” , which permits to overcome these restrictions. Previous work of Slud and Wei 
(1982) was of similar nature.
The spending function allocates the amount of type I error which can be spent at 
each analysis as a function of the proportion r  of the total information available.
r ,  called the information fraction, may be estimated as the fraction of the enrolled 
patients (or of the observed events) at a given time divided by the total number 
required on the basis of the sample size calculation. If r  specifies the position of 
each interim analysis along the trial, the alpha-spending function is a monotonically 
increasing function on the information fraction a(r), r  G [0,1], such that a(0) =  0 
and a ( l)  =  a , with a  the amount of type I error desired at the final analysis. a(r)  
is defined as the significance level which results if the study is stopped on either 
boundary when information fraction is r.
The group sequential boundaries of Pocock and O’Brien-Fleming can be, respec­
tively, approximated and reformulated in terms of the “spending function” as:
a i (r) =  2 -  2 OBF
=  cdn[l +  (e +  l)r] Pocock
(1.10)
(1.11)
where $  is the cumulative standard normal distribution function and eta is the 100(1— 
rj)th upper percentile of the same distribution.
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Many other spending functions have been constructed (Hwang and Shiy, 1990; 
Kim and Demets, 1987a).
At the ith inspection, Z{ and Vi are computed and compared with symmetric stop­
ping limits and U{ (li =  — Ui), chosen so that the probability of stopping at or before 
the current inspection under 9 = 0 is o (r). Then li and Ui are progressively chosen 
to satisfy:
P[Zj f  (lj , Uj for some j  = 1 , . . .  ,i)\ = o ( t) , i = 1 ,2, . . .  (1-12)
The number and timing of analyses have not to be pre-specified, but only the ma­
ximum amount of information to collect has to be anticipated in order to define an 
alpha-spending function procedure.
The calculation of CIs following the alpha-spending function approach is described 
in Kim and Demets (1987b).
1.2.2.4 Stochastic curtailm ent
Stochastic curtailment (Halperin et a l , 1982; Lan et al., 1982; Lan and Wittes, 1988), 
by taking into account the information available at a given interim analysis, tries to 
predict the final results that would be obtained would the trial continue until the 
planned end.
It is also referred as conditional power (CP) since it considers the test tha t would 
be performed using both data already available and data tha t would be collected 
if the trial were prolonged, and judges the properties of this test in the conditional 
distribution given what was observed so far.
Stochastic curtailed testing was proposed and used as a decisional tool for stopping
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a trial before its planned termination, when the treatments appear to be convincingly 
different or if they appear convincingly not different.
The CP is defined, at a given information fraction r  as the probability pT(9) that 
a statistical test will reject the null hypothesis Ho at the end of the study. The null 
hypothesis can be accepted at an information fraction r , assuming that a certain 
value of 6 is smaller than some prespecified value.
Since future data are unknown, several scenarios can be supposed, such as positive 
trend, negative trend or no trend at all. In fact, we can calculate the probability of 
different outcomes conditional on observing certain interim results. Thus, several 
values of 9 can be thought of, and consequently the CP values can be quite different 
depending upon the values chosen (Pepe and Anderson, 1992):
- the parameter value 9r as specified in the study design under H i ;
- the parameter value based on the data observed so far;
- the parameter value based on a limit of the Cl for the parameter estimate.
The decision to stop the study and accept the null hypothesis is based on a CP, 
calculated under a parameter value 9, falling below some prespecified value of proba­
bility 7r. Pepe and Anderson (1992) recommended values of 7r < 0.3. Betensky (1997) 
proposed values ranging from 0.1 (conservative) to 0.3 (nonconservative). Ware et al. 
(1985) used a value equivalent to 0.33.
Finally the optimal information fraction k must be chosen. For Pepe and Anderson 
(1992) values between 0.25 ond 0.5 have intuitive appeal.
Criticism to CP is that this approach can be very conservative and, furthermore, 
it does not give any information about 9 in terms of point and interval estimation, 
but only about the likely conclusion of the reference test.
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1.2.2.5 R epeated confidence intervals
The method of repeated confidence intervals (RCIs) creates a sequency of 100(1-7 ) 
percent CIs, one at each performed analysis, having the property tha t they all contain 
6 with probability 1 — 7 .
Denoting the ith interval by (6Li, Oui), the definitions is:
P[{0li, 0m) 3 0 for all i= l ,2 , ...] =  1 -  7 . (1-13)
Each individual interval, including the final one, satisfies
Pi(eLi,em ) 3  6 \>  1 - 7 . (i.i4 )
and therefore it is more conservative than a “classic” Cl, from whom therefore it 
must be distinguished, with error probabilities around 0.045 rather than 0.05. This 
conservatorism is the price to be paid for the great flexibility.
RCIs have been described by Jennison and Turnbull (1984, 1989, 1990). Durrle- 
man and Simon (1990) considered their application to non-inferiority trials.
When RCI approach is used as a sequential design, the trial is stopped as soon 
as the current RCI excludes the value corresponding to treatment equality. If the 
trial is stopped before the pre-planned end, the intervals will be conservative, since
the left-hand side of (1.13) will exceed 1 — 7 . In the same way, if the trial continues
beyond the planned end, no more valid intervals can be defined.
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1.2.3 Bayesian approach
The Bayesian philosophy of statistical inference differs from that underlying frequen­
tist approach, the main difference lying in the way they deal with probability. The 
difference is quite radical, and, although the conclusions reached may be qualitatively 
similar, the way of expressing and interpretating those conclusions are different.
For frequentists, the probability of an event is the limit of the relative frequency 
with which it occurs in series of suitably relevant observations in which it could occur. 
Bayesians, in contrast, interpretate probability as a personal degree of belief of a 
relevant observer concerning whether the event will or not will occur on a particular 
observation.
In frequentist analysis the unknown parameters in a statistical model are fixed 
but unknown quantities, and it is not possible to make probability about them. In 
Bayesian approach the parameters are random variables, having probability distri­
butions. In Bayesian approach, there may be as many different probabilities of an 
event as are observers, whereas for frequentists each event has a unique probabili­
ty. Frequentists talks about their probability as being “objective” , in contrast with 
Bayesian probability termed “subjective” , and since subjectivity is thought to con­
note arbitrariness and bias, they considered frequentist approach more suitable for 
scientific research.
On the other side, Bayesians assert that a subjective view of probability does 
not mean that probability is arbitrary and that their approach, using more availa­
ble information, can produce stronger results than frequentist method and is more 
appropriate for problems of decision making.
Bayesian probabilities are direct, since a Bayesian analysis of hypothesis results 
precisely in the probability that it is true, whereas the p-value for frequentist is 
an indirect measure, being the probability if we repeat the analysis many times to
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falsely reject the null hypothesis, even if it is usually interpreted to mean the more 
understandable Bayesian statement.
Bayesian intervals are called “credible intervals” to make it clear that they are 
different from frequentist confidence intervals. A 95% Cl for a certain parameter says 
that if we repeated the experiment under the same conditions many times, and we 
calculated an interval each time, then 95% of those intervals would contain the true, 
but unknown value of the parameter. The degree of probability of a credible interval 
is really the chance of the parameter lying in the particular interval.
1.2.3.1 Bayesian framework
Bayesians express their prior knowledge concerning a parameter of interest in a prior 
distribution function. Subsequently they observe data as a result of an experiment. 
The product of the prior distribution function and the information about this para­
meter contained in the data and expressed in the likelihood, leads to the posterior 
distribution function through the so called Bayes’ theorem.
The posterior distribution can thus be viewed as an update of the prior informa­
tion or as the prior belief modified by data. So while frequentist method uses only 
the likelihood, Bayesian uses both the likelihood and the prior information, the pos­
terior estimates being a compromise between prior and data estimates with a higher 
precision than either information sources separately.
In mathematical terms, let P(9) be the pre-study opinion or prior probability 
about the treatment effect size and P(data\9) be the likelihood of obtaining the ob­
served data, given the effect size, then
P{9\data) oc P(data\9)P(9) (1.15)
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is the posterior probability about the effect size, given the observed results, upon 
which any inference is derived.
In fact, when a Bayesian analysis reports a credible interval for a parameter, this 
is a posterior interval, derived from the parameter’s posterior distribution, based not 
only on the data but also on whatever other information or knowledge the investigator 
possesses.
When the prior information is very weak, relative to data information, the prior 
distribution gets so little weight in Bayes’ theorem that the posterior distribution 
is effectively just the likelihood. In this situation Bayesian methods lead to similar 
inferences to conventional frequentist methods.
1.2.3.2 Prior distribution
The prior information allows Bayesian approach to access more information and thus 
to produce stronger inferences, even though it is the main butt of criticisms of fre- 
quentists due to its subjectivity. This drawback can be overcome, by choosing a prior 
information based on a widespread evidence and examining a sufficient number of 
observations, so that differences in prior positions can be shaded.
We need to specify the prior distribution with sufficient reliability and accuracy. It 
is important to note that the choice of the prior may not be necessarily unique, but a 
range of prior distributions could be presented, thus reflecting different perspectives. 
This can include the subjective prior opinion of the trial investigators and/or other 
experts, as well as the results of previous similar studies.
Possible priors include (Spiegelhalter et a l , 1993; Parmar et a l , 1994):
- uninformative prior, representing a lack of prior opinion or information as to 
the likely treatment difference. It is the more unrealistic prior, corresponding
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more or less to the frequentist approach of significance testing. Nevertheless 
such a prior is the least subjective and can be used as a reference against which 
to measure the impact of the choice of other priors;
- clinical prior, representing the opinion of experts. It may change during the 
course of the trial, since the clinician view can be influenced for instance by 
new external evidence;
- sceptical prior, representing the opinion of someone who, unenthusiastic about 
the treatment under study, thinks that there is only a small probability tha t the 
alternative hypothesis is likely to be true. It represents some scepticism about 
the treatment effect and its conservatorism leads to a behaviour comparable 
to that of group sequential designs (Freedman and Spiegelhalter, 1989). It is 
useful in order to counteract over-enthusiastic opinion due to extremely positive 
results that could be observed by chance during a clinical trial;
- enthusiastic prior, representing the opinion of individuals who are persuaded 
that experimental treatment effect is greater than control.
The argument in favor of representing no prior information is tha t this avoids any 
criticism about subjectivity. There have been numerous attempts to find a formula 
for representing prior ignorance, but without any consensus.
The idea of using “sceptical” prior is that if a sceptic can be persuaded by the data, 
then anyone with a less sceptical prior position would also be persuaded, denoting 
that the data are strong enough to reach a firm conclusion. If, on the other hand, the 
data are not strong enough to yield a high posterior probability for that hypothesis, 
then we should not yet claim any definite inference about it. This prior can be useful 
to counterbalance early positive results, which could be lead to premature termination 
of the study.
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On the other side, the enthusiatic prior distribution is useful when initial results 
suggest a detrimental effect of the experimental treatment, again to avoid a premature 
termination of the trial.
As already explained, the usual approach to specifying a prior distribution for 
some parameters consists of first specifying a few features of the distribution, such as 
a prior expectation and some measure of prior uncertainty (e.g. the prior variance), 
then choosing a suitable distribution to fit these features.
It is sensible to make choice of distributions on grounds of simplicity and con­
venience. Mathematically, in some simple statistical problems there exist classes of 
priors known as conjugate priors tha t are particularly convenient.
In fact, while the likelihood function is often determined by the nature of data, as 
a rule, prior distribution can be of any form. In practice the analysis is simpler if the 
prior distribution is chosen so that the posterior is a member of the same distributional 
family. Such a family is called “conjugated” for that particular likelihood function.
As an example, when both the prior and the likelihood are normal, also the 
posterior has a normal distribution with mean lying between the mean of the prior 
and the observed effect. The posterior distribution variance is smaller than the prior 
one, since further data have been incorporated (Abrams et al., 1994).
For time to event data, Tsiatis (1982) has shown that the quantity 4Z /n , where n 
is the total observed number of events in the two groups, has an asymptotic normal 
distribution with mean 9 and variance 4/n . Therefore, supposing that the prior di­
stribution for the 1 n(HR)  is normal with mean fi0 and variance <7q, and the likelihood 
from the data has mean /if, and variance ct|, then the posterior distribution is also 
normally distributed with mean ^ oq'L+^a°) anc[ variance
17 (CTo + CTi )  (*o+ a i )
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1.2.3.3 Trial m onitoring
When cumulative data from a trial are analyzed sequentially following the Bayesian 
approach, the posterior distribution describes the currently available information 
about the parameter of interest. This information can be used to decide whether 
to stop the study because enough evidence is already gathered or whether additional 
evidence is needed.
Two important features of Bayesian analysis are tha t all available information can 
be used in deciding whether to stop a trial. First, the decision of an early termination 
may depend not only on data from the trial but also on external information, which 
may have become available after the beginning of the study. In this latter case 
the prior may be changed in order to take into consideration this new information. 
Second, it is more flexible, since interim analyses can be introduced without affecting 
the final conclusions; they do not need to be planned in advance and there is no 
penalty for the repeated analyses, due to the lack of dependence on study design.
Decision theory provides another good example of the flexibility of Bayesian in­
ference. In this theory we have a set of possible decisions and an utility function that 
specifies how good it would be to make a particular decision, if the parameters turned 
out to have particular values. For instance, for a hypothesis test we could define an 
utility function that states it would be good (high utility) to accept the hypothesis 
if it turned out to be true, or to reject it if it turned out to be false, but otherwise 
the utility would be low.
If we knew the parameters, it would be easy to reach a decision, since we would 
just choose the decision with the largest utility for those values of the parameters. 
However, the parameters are generally unknown. Decision theory says we should 
choose the decision with the highest (posterior) expected utility. This expectation is 
the value of the utility, averaged with the posterior distribution of the parameters.
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There are two Bayesian approaches to stopping decision. The first is the decision 
theoretic approach (Anscombe, 1963; Colton, 1963), in which a fixed total number 
of patients is assumed and costs and utilities to various decisions and outcomes are 
assigned: the consequences of continuing and of stopping a trial are weighted using 
the current distribution of 6. In practice, since it is difficult to quantify the number 
of the patients and the costs, this approach has been criticized (Peto, 1985) and 
rarely applicated. The second Bayesian approach is enterely based on the posterior 
distribution of 6. It is often useful to present the results of an interim analysis under 
several alternative prior distributions, so that the impact of the data may be reviewed 
according to different levels of scepticism.
Chapter 2 
Aims
Several important questions have been raised about decision of stopping a trial early, 
and on what basis to reach such a decision. Differences between treatments may be 
larger than expected or unanticipated adverse effects may occur, and either of these 
may justify early termination of a trial. Early stopping may sometimes be suggested 
because continuing a trial would not provide sufficiently useful information to warrant 
continuation. Existing evidence from outside the trial, such as meta-analyses of data 
from comparable trials, other existing evidence external to the trial and the nature 
of the condition and its alternative treatments may be also taken into consideration 
when deciding to stop or continue a trial. Data from the trial may later constitute 
the base for management of future patients, therefore the evidence should also be 
sufficiently convincing to the wider clinical and patient communities to determine 
future practice.
In chronic life-threatening diseases, like cancer, evidence of early therapeutic - 
benefits may be even more compelling than in other diseases and the detection of 
the best trade-off between obtaining results as earlier as possible and getting good 
estimation of the magnitude of treatment effect is particularly important.
A range of formal statistical approaches can be used as a basis for judging at what
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point such differences are so extreme as to be sufficiently unlikely to reflect the play of 
chance. These analyses help to control for errors in decision making and estimation; 
however, although interim analyses in clinical trials are widely known, information on 
explicit adoption of some form of planned monitoring, even in long-term trials, is still 
scarce and basically driven by the published reports of studies, which rarely include 
details on both the strategies for data monitoring and interim analysis plan. Further 
research is therefore needed for comparing the performance of different statistical 
approaches in real life situations.
It seems therefore of interest to investigate the forms of monitoring used in cancer 
clinical trials and in particular to gather information on the role of interim analyses 
in the data monitoring of a clinical trial.
More specifically, the project addresses the following issues:
- what are the operative characteristics of different interim analysis approaches;
- how often interim analyses are used and which types of statistical analysis are 
more frequently adopted;
- how information derived from statistical analyses is taken into consideration in 
the decisional process.
Regarding the first aim, research will focus on comparison of the more commonly 
used statistical approaches to interim analysis on real data derived from cancer cli­
nical studies, in order to increase knowledge on their relative efficiency, in terms of 
anticipation of the final effect and accuracy of the effect size estimation. Potentially 
influencing factors, such as severity of disease, magnitude of treatment effect and 
number of analyses will be taken into consideration, too.
As for the second: to investigate how often interim analyses are used and which 
types of analysis are more frequently adopted, the project will focus mainly on the
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prevalence of the different types of interim analysis and of data monitoring in clinical 
trials. Source of investigation will be literature data and the protocols of cancer 
clinical trials included in Italian registry of clinical trials.
The final aim, focusing on the actual impact of results of interim analyses on the 
decision of modifying the planned study conduct, deals with two separate tasks: first, 
to provide information on how often an early termination is caused by results of an 
interim analysis. For this proposal, causes of early interruption will be investigated 
based on published papers of preliminary or early clinical trial results. Secondly, to 
obtain information from the literature on the modality of implementation of interim 
analyses in the data monitoring, investigating which are the more reported forms and 
rules for such a process.
Chapter 3
M ethods
3.1 Comparison of different statistical approaches
3.1.1 M onitoring approaches
Among all those proposed for study monitoring, the following methods have been
considered:
1. F req u en tis t
- Nai've, in which no adjustment for multiple testing has been used;
- a lp h a-sp en d in g  func tion  (Lan et al., 1983; DeMets et al., 1994) with 
OBF boundaries. The spending function controls the rate at which the 
total a  error is spent as a continuous function of information fraction avai­
lable at the moment of the analysis and thus determines the corresponding 
boundary. The nominal significance levels at each analysis depend on the 
prespecified overall a  error, and on the number of analyses. At the final 
analysis, the nominal significance level is close to tha t of the conventional 
fixed sample design (see Section 1.2.2.3);
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- T rian g u lar te s t, introduced by Whitehead (1983, 1992, 1994), in which 
the boundaries are a function of the information fraction and the trial 
stops when the sample path crosses a boundary. The boundaries depend 
on prespecified a  and j3 errors, on the expected value of Or , and on the 
expected rate of events in the control group. After each analysis, in order 
to maintain the total a  error at the desired level, boundaries are adjusted 
thus assuming a “christmas tree shape” (see Section 1.2.2.1);
- R e s tr ic te d  p ro ced u re  (Armitage, 1957, 1975; Whitehead, 1992), ano­
ther boundary test, which if the slope value is set equal to zero, as in our 
case, produces boundaries similar to those suggested by O’Brien and Fle­
ming. Like the triangular test, also in the restricted procedure boundaries 
depend on a, (3 and O r  (see Section 1.2.2.1);
2. B ayesian, choosing three different prior distributions (Fayers et al., 1997)
- U n in fo rm ative  p rio r, tha t contains no information about prior opinion 
on treatment effect:
U ninform ative prior ~  N  (ln(l), oo).
Even if a normal distribution cannot have an infinite variance and therefore 
this is an improper uniform distribution, it will anyway used for mathe­
matical considerations;
- S cep tical p rio r, with mean equal to 0 and a precision such th a t the 
prior probability of a true effect as large or larger than what stated by the 
alternative hypothesis is small, say 5%. The sceptical prior is equivalent 
to having performed a trial with sample size equal to Np subjects all of 
whom have died, and in which no difference has been observed between
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arms:
Sceptical prior ~  N  ^ln(l), —  j  ;
- E n th u sias tic  p rio r, corresponding to consider as best guess the alterna­
tive hypothesis and having the same precision as the sceptical prior:
Entusiastic prior ~  N  I In(HRi),
In the Bayesian approach, stopping rules are based on the posterior probabilities. 
A reasonable criterion is that the posterior probability of one treatment being better, 
using a sceptical prior opinion, is at least 95%. Alternatively, if a non-zero target is 
sought, a reasonable criterion might be to accept a posterior probability of at least 
90% (Fayers et al., 1997) (see also Section 1.2.3).
3.1.2 R eanalyzed clinical trials
Three published phase III trials, coordinated in Italy by the Istituto di Ricerche 
Farmacologiche “Mario Negri” of Milan, were considered.
All these studies were aimed at demonstrating superiority, in terms of overall 
survival, of the experimental treatment versus control. They were chosen to represent 
different clinical settings for long-term prognosis, recruitment duration and expected, 
effect size, as well as different conclusions that a clinical trial may reach.
where ln(77i?i) is the natural logarithm of the HR under the alternative 
hypothesis.
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ICON 3 Trial (The International Collaborative Ovarian Neoplasm (ICON) Group,
2002) showed no statistically significant difference between arms, while ICON 4/AGO- 
OVAR 2.2 study (The ICON and AGO Collaborators, 2003) and the GIVIO/SITAC 
01 Study (Zaniboni et al., 1998) demonstrated the superiority of experimental treat­
ment.
For each trial, the initial hypothesis on the two-sided a  error rate, the power, the 
expected benefit of the experimental treatment over control and the expected rate of 
events in the control group were retrieved from the protocols. Using this information, 
for each trial the monitoring process was rebuilt according to the previously described 
methods.
Our intention was to compare conclusions drawn from each monitoring method 
with those actually obtained.
3.1.2.1 ICO N 3 Trial
This study was aimed at comparing the safety and efficacy of paclitaxel plus carbo- 
platin with a control of either cyclophosphamide, doxorubicin and cisplatin (CAP) 
or carboplatin alone in women with advanced ovarian cancer.
“. . .A n  independent data-monitoring and ethics committee (DSMC), comprising 
two clinicians and one statistician who had no involvement in the trial, was establi­
shed to review the progress and confidential unmasked results, and any other relevant 
external evidence, about once a year during the accrual period. The committee did not 
follow any predetermined statistical stopping rules... We expected that 2-year survival 
would be about 50% in the control groups of the trial. With a 2:1 ratio in favour 
of control, an initial accrual target of 1000 patients in the control groups was set to 
allow the reliable detection of an absolute difference in 2-year survival of 10% (from 
50% to 60%) with 85% power at the 5% significance level. This absolute difference
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translates into a hazard ratio of 0.74■ With 1000 patients entered (and about 460 
deaths), the 95% Cl for a difference of 10% would be estimated as 4~15%. A t their 
first meeting on July 1, 1996, the DSMC recommended that the trial size be increased 
to allow smaller differences to be detected reliably. This recommendation was en­
dorsed by collaborators at meetings in July, 1996, and a new target of 2000 patients 
was agreed. This target accrual was sufficient to allow the reliable detection of an 
absolute difference of 7%> in 2-year survival (from 50% to 57%) with 85% power at 
the 5% significance level, corresponding to a hazard ratio of 0.81. With 2000 patients 
entered (and about 955 deaths), the 95% Cl for an absolute difference of 7% would be 
estimated as 3-11%. The DSMC reconsidered the evidence at the end of May, 1997, 
the week after the results of OV 10 and GOG-132 became available, when 1254 Pa~ 
tients had been randomised into ICON 3. The committee recommended that the trial 
continue recruitment to 2000 patients, and this suggestion was endorsed by collabo­
rators at meetings early in June, 1997... ”.
Between February, 1995 and October, 1998 2074 women were therefore enrolled. The 
final analysis was performed at a median follow-up time of 51 months after the ob­
servation of 1286 events. The estimate of the treatment effect resulted in a hazard 
ratio of 0.98 (95% Cl 0.87-1.10) with a p-value of 0.74, using the log-rank test.
The authors concluded that " . .up to 5 years from treatment, single-agent carbo- 
platin, CAP, and paclitaxel plus carboplatin are all safe and show similar effective­
ness as first-line treatments for women requiring chemotherapy for ovarian cancer. 
Of these three treatments, carboplatin might be regarded as the preferred treatment 
because of its better toxicity profile,... ”.
M ethods 42
3.1.2.2 ICO N 4 / AGO-OVAR 2.2 Trial
Run as two parallel trials, this study investigated whether paclitaxel should be given 
in addition to platinum-based chemotherapy in patients with ovarian cancer relapsing 
6 or more months after the end of the previous line of platinum-based chemotherapy, 
and therefore judged to have platinum-sensitive disease and who would otherwise be 
treated with more conventional platinum-containing regimens.
“ .. For ICON 4, an independent data monitoring and ethics committee was e- 
stablished, of two clinicians and one statistician who had no involvement in the trial 
Progress and unmasked results of the trial and any other relevant external evidence 
were reviewed roughly once yearly during the accrual period. The committee followed 
no predetermined statistical stopping rules. A data monitoring and ethics committee
was not established for the AGO trial__
. . .  When the original sample size calculations were made, few data were available 
on the outcome of relapsed ovarian cancer. We expected that 2-year survival would be 
about 5% in the control group and the absolute difference in 2-year survival of no more 
than 5-10% (5-10%) with 95% power at the 5% significance level, corresponding to a 
hazard ratio of 0.77. A t the final analysis on Feb 8, 2001, the data monitoring and 
ethics committee noted that the survival in the control group was much higher than in 
the original power calculations; two-year survival in the conventional treatment group 
was around 50%. We therefore revised the power calculations. We calculated that 800 
patients would be sufficient to detect reliably an absolute difference of 11% in 2-year 
survival (50-61%) with about 90% power at the 5% significance level, corresponding
to a hazard ratio of 0.71. Hence the target accrual remained unchanged__
.. .From January 1996 to March 2002, 802 patients were enrolled in the study.
.. .B y  March, 2003, with a median follow-up of 4% months, 530 patients had died. 
Survival curves showed a hazard ratio of 0.82 (95% Cl 0.69-0.97, p= 0.02)... ”.
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The authors concluded “Our findings suggest a beneficial effect for paclitaxel in 
combination with platinum chemotherapy on survival and progression-free survival 
among patients with platinum-sensitive relapsed ovarian cancer
3.1.2.3 GIVIO/ SITAC 01 Trial
This study was designed to assess whether 5-fluorouracil and high dose of folinic acid 
(HD-FUFA) would increase the overall survival of patients with resectable Dukes B 
and C colon carcinoma. Early results were published as a part of an international 
multicenter pooled analysis (IMPACT Investigators, 1995).
The original plan for the study was to detect a 30% relative mortality reduction 
at 80% power with a conventional two-tailed test of 5%. No DSMC was established 
for the study.
Overall, 888 patients were randomised, while 869 were considered eligible and 
therefore included in the analysis. The median follow-up time for the HD-FUFA and 
control arms were 65 and 63 months, respectively. HD-FUFA significantly reduced 
the rate of mortality of 25% (95% Cl 5-41%, p=0.02): there were 120 deaths in the 
treatment arm and 159 in the control arm.
Authors concluded that “this study confirmed that adjuvant therapy clearly re­
duced mortality among patients with colon carcinoma. .. ”.
The main characteristics of the three studies are summarized in Table 3.1.
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Table 3.1: M ain  ch arac te ris tic s  of th e  rean aly sed  clinical tr ia ls
S tu d y
D u ra tio n  (yrs) of
P a tie n ts E ven ts
O bserved  H R  
(95% C l) Ps tu d y enro llm en t
ICON 3 7.7 3.7 2074 1286 0.98 (0.87-1.10) 0.74
ICON 4 6.8 6.2 802 530 0.82 (0.69-0.97) 0.02
SITAC 01 7.4 3.0 869 280 0.75 (0.59-0.95) 0.02
3.1.3 Interim  analysis planning
For each study, interim analyses were performed at equal intervals of events, precisely 
at 25, 50, 75 and 100% of the total number of events observed. In reality, to con­
duct analyses at constant time intervals turns out to be more practicable, because it 
allows to schedule in advance the DSMC meetings. However, it is anticipated that 
results are not affected by the approach chosen to select the cut points of the analysis 
(Fleming and DeMets, 1993).
3.1.4 S tatistica l analysis
Individual patient data retrieved included:
- Patient code;
- Randomisation date;
- Treatment code;
- Event code;
- Date of event, if present, otherwise date of last follow-up.
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Thus retrospectively the progress of each trial was rebuilt and the different moni­
toring procedures were applied. The date the trial would have been stopped was then 
determined according to each method. All the sequential re-analyses are idealized, in 
tha t all events had occurred by x years are included in the analysis at x  years, while 
in the practice, this is seldom possible, since a reporting lag is always detected.
Differences in survival between treatments were assessed using the log-rank test. 
HRs and their 95% CIs were calculated using Cox’s proportional hazards regression 
model (Cox, 1972) at the date of stopping decision provided by each method.
When group sequential test procedures were used, standard confidence intervals 
were adjusted taking into account the sequential nature of analyses. For triangular 
test and restricted procedure, if not otherwise specified, the 95% CIs for the estimate 
of the HR were computed using the Woodroofe approach, that allows for the fact 
that on termination of a sequential trial the distribution of z may not be the standard 
normal (Woodroofe, 1992).
Point and credibility interval estimates are easily calculable using the Bayesian 
methods inherent in the non informative, sceptical and enthusiatic schemes.
The monitoring and the sequential analyses using the triangular test and the 
restricted procedure were performed with the Planning and Evaluation of Sequen­
tial Trials (PEST 4.0) statistical software (Medical and Pharmaceutical Statistics 
Research Unit, 2000), kindly provided by the authors.
The Lan and DeMets method was performed both with the program called LAN- 
DEM (Reboussin et al. 1996, 2000), publicly available on Internet, and with East 
software (Cytel Software Corporation, East Cambridge: Cytel Software Corporation,
2003).
Otherwise, statistical analyses were computed using SAS (Statistical Analysis Sys­
tem, SAS Institute Inc., Cary, NC, US, Version 8.20) software.
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3.1.5 Sim ulations
We evaluated the properties of the frequentist methods by computer simulations, too.
A SAS macro routine, reported in Appendix A, was developed for computing 
distribution of ln(HR) at specific time points. The routine allowed for the choice of:
- number of interim analyses;
- underlying hazard ratio;
- probability of event at a particolar time point;
- accrual duration time (years);
- total study duration (years).
Assumptions were made on the uniformity of accrual over time, on exponential 
distribution of survival times and on normality of distribution of In (HR) at each cut 
point.
For each of the three studies (ICON 3, ICON 4, GIVIO/SITAC 01) a total of 
10000 runs (denoted trials) were generated in order to compare the naive approach, 
alpha-spending function with OBF boundaries, the triangular test and the restricted 
procedure, having the fixed sample size design as benchmark.
We used the actual values of the underlying hazard ratio, of the probability of the 
event, of the total duration of the study, as well as of the accrual period.
We also considered the consequences of performing the analysis four times (at 25, 
50, 75 and 100% of the total number of observed events) and eight times (at 12.5, 
25, 37.5, 50, 62.5, 75, 87.5 and 100%).
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3.2 Early reports in scientific literature
In order to investigate the characteristics of early publications in the scientific lite­
rature, we performed an electronic search, focusing on the description of the type of 
statistical approaches used.
Source of investigation of literature data was PubMed, available via Entrez re­
trieval system, and developed by the National Center of Biotechnology Information 
(NCBI) and by the National Library of Medicine (NLM), located at the National 
Institute of Health in Bethesda (United States).
PubMed was designed to provide access to citations from biomedical literature, as 
well as to full-text articles at journal Web sites and other related Web resources. It 
also provides access to bibliographic information that includes MEDLINE, OLDMED- 
LINE, and citations that precede the date when the journal was selected for MED­
LINE indexing, and some additional life science journals, submitting full text to 
PubMedCentral and receiving a qualitative review by NLM.
Research strategy focused on cancer randomised clinical trials (RCTs), published 
from January 2000 to February 2005, and presenting either in the title or in the 
abstract at least one of the the following terms: “interim”, “early” , “preliminary” , 
“pilot” .
Formally, the research was conducted in the following way:
Field: T it le /A b s tra c t , Limits: P u b lica tio n  D a te  from  2000, R an d o m ized  
C on tro lled  T rial, C ancer
(preliminary [Title/Abstract] OR early [Title/Abstract] OR interim [Title/Abstract] 
OR pilot [Title/Abstract] AND Randomized Controlled Trial [ptyp] AND cancer [sb] 
AND ( “2002” [PDAT]: “3000” [PDAT)].
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In order to select studies for further assessments, two independent reviewers 
scanned the title, abstract section and keywords of every retrieved record. Pull articles 
were taken into account, if the information given suggested that:
- the study was a randomized clinical trial (RCT) in oncological field;
- the primary endpoint was a time to event variable;
- the publication concerned the results of an analysis different from that planned 
as final.
If there was any doubt regarding these criteria from the information given in the 
title and abstract, the full article was retrieved for clarification. If different opinions 
existed, they were resolved by discussion.
A template data extraction form was developed and tested in a pilot phase. Data 
extraction have been performed independently by two evaluators. Differences in data 
extraction was resolved by consensus with a third reviewer, referring back to the 
original article. This form included the following items:
- Journal;
- Journal impact factor;
- Year of publication;
- Type of disease;
- Stage of disease (early/advanced);
- Experimental treatment;
- Control treatment;
- Reason for publication (Interim analysis/ Preliminary results not related to 
primary efficacy endpoint);
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- Presence of DSMC;
- Presence of planned stopping rules;
- Type of stopping rules;
- Analysis performed before accrual termination (Yes/No);
- Results (Study continued/Study stopped for futility/Study stopped for effi­
cacy /Study stopped for other reasons);
- Planned sample size.
Results were described using absolute and relative frequencies, and contingency 
tables.
A multiple linear regression model was used for estimating the association between 
importance of journal chosen for publication, represented by the impact factor, the 
decision of stopping the trial based on results of interim analysis, and presence of 
DSMC.
A logistic regression model was also performed in order to analyse the association 
among decision following early analysis results and potential determinants, such as 
presence of DSMC, presence of interim analysis plan and study sample size.
Analysis was performed using SAS (Statistical Analysis System, SAS Institute 
Inc., Cary, NC, US, Version 8.20) software.
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3.3 U se of interim analyses in randomized onco­
logical trials
We also investigated the kind of interim analyses planned in clinical oncological trials 
currently submitted for approval to Italian Ethics Committees (ECs).
Reason for this research stems from the observation that analysis of published 
trials may reflect the criteria adopted by trials planned even several years before and 
as a consequence data derived even from the most recent published literature may 
not be completely appropriate to represent the current trends of interim analysis and 
data monitoring use.
Moreover in published literature the quality of details relative to the description 
of statistical methods is often scarce, and it is possible that, despite the accuracy 
of literature search strategy, the information regarding the approaches adopted for 
monitoring clinical trials is not completely captured.
Since 2002 an electronic registry of all clinical trials submitted to ECs is active 
in Italy. The registry was initially aimed at mapping clinical researches conducted in 
Italy and at facilitating the exchange of information among ECs, their coordination, 
and a shared decision on authorizing the launch of a particular clinical trial. It may 
also offer a great opportunity for conducting epidemiological public health researches 
on clinical trial strategies, by investigating the type and relevance of current clinical 
research questions, as well as the quality of the design and other methodological 
criteria adopted by researches currently ongoing in Italy.
Our project is actually one of the first examples of research which takes advantage 
of the registry, because in order to investigate how often interim analyses are used 
and which types of analysis are more frequent in clinical trials conducted in oncology, 
we had the opportunity of evaluating the protocols in the “Osservatorio Nazionale 
sulla Sperimentazione Clinica dei Farmaci”, OsSC (National Monitoring Centre for
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Clinical Trials) of Italian Ministry of Health1.
We assessed protocols available in the “Osservatorio” database, relative to onco­
logical studies submitted to ECs from January 1st, 2000 to May 18</l, 2005, restricting 
the evaluation to protocols of randomised studies with a time to event endpoint, such 
as overall survival (OS) or progression free survival (PFS).
Similarly to the previous project on early reports in scientific literature, a template 
data extraction form was developed and tested in a pilot phase. Data extraction have 
been performed independently by two evaluators. Differences in data extraction were 
resolved by consensus with a third reviewer, referring back to the original protocol. 
The form included the following items:
- Identification number;
1T h e  “O s s e r v a to r io ” i s  a n  in s t r u m e n t  d e v e lo p e d  t o  im p r o v e  c o o r d in a t io n  a n d  s u r v e i lla n c e  o f  
c l in ic a l  t r ia ls  o n  d r u g s  c o n d u c te d  in  I ta ly .
I n  fa c t ,  t o  b e  in i t ia t e d ,  e v e r y  tr ia l  h a s  t o  o b ta in  t h e  r e le a s e  o f  t h e  m o t iv a t e d  o p in io n  o f  t h e  E C  t h a t  
h a s  t o  ta k e  in to  a c c o u n t , w h ile  e v a lu a t in g  t h e  s t u d y  p r o to c o l ,  i t s  s c ie n t if ic  r e le v a n c e  a n d  t e c h n ic a l  
a s p e c ts ,  s u c h  a s  in fo r m e d  c o n s e n t , a s s u r a n c e  a n d  a d e q u a c y  o f  m e d ic a l f a c i l it ie s .  T h e  f ir s t  s t e p  in  
su c h  a  p r o c e s s , i s  t h e  c e n tr a l r e g is tr a t io n  w i t h  t h e  O sS C . A fte r w a r d s , t h e  r e s u l t s  o f  t h e  a s s e s s m e n t  
m a d e  b y  e a c h  lo c a l  E C , t o g e th e r  w i t h  t h e  d e ta i ls  o f  e a c h  s t u d y  -  t y p e ,  p h a s e ,  t h e r a p e u t ic  c a t e g o r ie s ,  
e t c . ,  h a v e  a ls o  t o  b e  r e p o r te d  w i t h in  t h e  O sS C  d a ta b a s e .  T h e n , t h is  in fo r m a t io n  b e c o m e s  a c c e s s ib le  
t o  a l l  E C s , s o  t h a t  t h e  a s s e s s m e n t  p r o c e s s  b e c o m e s  a s  t r a n s p a r e n t  a s  p o s s ib le .  A c c e s s ,  h o w e v e r , is  
r e s tr ic te d  t o  E C s  a n d  d a ta  a re  n o t  a v a ila b le  t o  t h e  g e n e r a l p u b lic  y e t .
T h e  in fo r m a t iv e  s u p p o r t  o f  t h e  “O s s e r v a to r io ” c o n s is t s  o f  th r e e  o n - l in e  r e g is te r s  w h ic h  fo r m  t h e
d a ta b a s e  o f  c l in ic a l  tr ia ls .  T h e  M in is t r y  o f  H e a lth , t h e  lo c a l  E C s , t h e  s p o n s o r s , t h e  R e g io n s  a n d  t h e
a u to n o m o u s  P r o v in c e s  c a n  a c c e s s  t h e  in fo r m a t io n  o n  t h e s e  r e g is te r s , a c c o r d in g  t o  th e ir  o r g a n iz a t io n a l  
n e e d s . T h e  r e g is te r s  a r e  t h e  fo llo w in g :
-  a  R e g is te r  o f  t h e  lo c a l  e th ic s  c o m m it te e s ;
-  a  R e g is te r  o f  p r iv a te  c l in ic a l  s ite s ;
-  a  R e g is te r  o f  c l in ic a l  tr ia ls .
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- Experimental phase (I/II/III/IV );
- Year of EC opinion release (year for study protocols not yet released was con­
ventionally established as 2005);
- Type of sponsor (Profit/No profit);
- Involved countries (Italy/Europe/Worlwide);
- Study objective (Superiority/Non inferiority/Mixed);
- Setting [Early (adjuvant or neoadjuvant)/Advanced (locally advanced or metasta­
tic or mixed) for solid tumors; pediatric/adult for haematological tumors];
- Primary endpoint (OS/PFS/Event Free Survival/Recurrent Free Survival);
- Disease localization;
- Number of arms;
- Experimental treatment;
- Expected number of events at the end of the study;
- Expected number of patients at the end of the study;
- Planned number of centers;
- Study total duration (months);
- Accrual duration (months);
- Follow-up duration (months);
- Presence of interim analyses;
- Number of interim analyses, if planned;
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- Type of interim analyses, if planned;
- Objective of interim analyses (Efficacy/Safety), if planned;
- Presence and type of timing of interim analyses, if planned;
- Presence of DSMC;
- Composition of DSMC, if present;
- Tasks of DSMC, if present.
Results were described using adequate descriptive statistics, such as absolute and 
relative frequencies, and contingency tables.
A logistic regression model was also performed in order to assess the association 
among presence of interim analyses and/or DSMC and potential determinants, such 
as type of sponsor, involved countries and year of submission.
Analysis was performed using SAS (Statistical Analysis System, SAS Institute 
Inc., Cary, NC, US, Version 8.20) software.
Chapter 4
R esults
4.1 Comparison of different statistical approaches
The results of the analyses performed applying the different statistical approaches on 
real data are reported later on.
Data derived by simulations are also presented with the purpose of quantifying the 
probability of early stopping and the estimates of treatment effect, when calculated 
in case of early interruption.
The most important assumption that should be taken into account for interpreting 
these results is that the estimates found at the end of the study are to be considered 
as the “true” treatment effect and therefore taken as reference.
Analyses were performed assuming interim looks at regular proportion of events: 
in order to assess the effect of an increase in the number of looks, the simulations 
were performed twice: firstly adopting four analyses, then eight analyses.
For each study, results obtained according to the previously described approaches 
are presented later on. In the relevant tables, the red colour has been used for 
frequentist methods to emphasize an analysis in which the relevant stopping boundary 
has been crossed. For Bayesian approach it denotes the results of an analysis in which
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either the posterior probability of one treatment being better using a sceptical prior 
is at least 95 per cent or, if a non-zero target improvement is sought, a posterior 
probability of at least 90 per cent, as well as a 95% credibility interval tha t does not 
include the value of one.
In the tables the term “z-value” refers to the standardized normal statistic, while 
in the figures Z  = —Z* is reported, where Z* is the logrank statistic, according to 
Whitehead (1983) (see Section 1.2.1).
All reported p-values are one-sided.
4.1.1 ICO N 3 Trial
Tables 4.1, 4.2, 4.3 and 4.4 report the results of naive method (analysis without 
adjustments), alpha-spending function with OBF boundaries, triangular test, and 
restricted procedure, respectively. Plot of results of these analyses are also reported 
in Figures 4.1, 4.2, 4.3.
Table 4.5 shows estimates (HRs and 95% CIs) calculated at study closure, con­
sidered as the first crossed boundary or the last scheduled analysis, according to the 
results obtained by each considered method.
Tables 4.6, 4.7 and 4.8 report the results obtained adopting Bayesian approach.
Of note, the naive method, which for all analyses considers as stopping boundary 
the value of the standardized normal statistic equal to 1.96, corresponding to an 
one-sided p-value equal to 0.025, would have conducted to early stopping at the 
second analysis (HR=0.84; 95% Cl: 0.71-0.99; p=0.02, one sided), with a relative 
overestimate of 13%.
The triangular test, which allows for an asymmetric power design, requiring a 
high effect magnitude to detect superiority of experimental treatment, while more
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relaxed boundaries against refusal of the null hypothesis, would have conducted to 
conclude for futility at the fourth (final) analysis. The observed p-value was 0.10, the 
unbiased estimate of the HR was 0.95 (95% Cl: 0.85-1.08).
OBF approach and restricted procedure, which both require very extreme results 
in order to stop, particularly in the early analyses, show superimposable results: with 
these approaches the study would have not been interrupted.
Although it is rather difficult to directly compare Bayesian with frequentist ap­
proaches, Bayesian approach showed that under the sceptical prior, the point estimate 
at the second look is 0.88 and the relative overestimate is reduced to 8%. The proba­
bility of an effect size larger than zero is 96% at the second look, while the probability 
of an effect size larger than 2.5% is reduced to 76%, but the probability to obtain 
at least a 5% reduction in mortality is 36%, suggesting that the benefit, if any, is 
very small. At the end of the study, the probability of some effect is still quite high 
under the sceptical prior (71%), but the chance to have a clinically relevant effect 
(say at least 5% reduction in mortality) is 1% under the sceptical and 6% under the 
“enthusiastic” prior, respectively.
Table 4.9 reports the results of the simulation with four looks.
As also summarized in Table 4.31, using the naive method, the overall chance of 
early stopping (calculated as the percent of the number of trials with HR point esti­
mate outside the boundaries, divided by the total number of trials) was 17.2%: 14.9% 
of trials crossed the lower boundary, indicating an effect in favour of experimental 
arm, while 2.3% crossed the upper boundary. The larger proportion of trials outside 
the boundaries was observed in the first and second looks (58% of trials crossing the 
lower boundary and 77% of trials crossing the upper boundary occurred in these first 
two analyses).
The median HR of trials with results crossing the lower boundary ranged from 
0.77 to 0.89, and on the average, the overestimate was 13.6%. For trials stopped
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because the upper boundary was crossed, the median HR ranged from 1.12 to 1.28, 
with an underestimate of effect equal to 27%.
Simulation adopting alpha-spending function with OBF boundaries and restricted 
procedure produced similar results.
For alpha-spending function the percentage of early stopping was 9.5% (0.6% at 
upper boundary and 8.9% at the lower boundary) and the chances of early stopping 
were higher at the last two analyses (93.4% of early interruptions for crossing the 
lower boundary and 96.5% of interruptions for crossing the upper boundary). The 
median HR of trials with results crossing the lower boundary ranged from 0.78 to 
0.88, and on the average, the overestimate was 10.9%. For trials stopped because 
the upper boundary was crossed, the median HR ranged from 1.13 to 1.30, with an 
underestimate of effect equal to 19%.
A similar pattern was produced by the restricted procedure: the percentage of 
early stopping was 10.6% (0.7% at upper boundary and 9.9% at the lower boundary) 
and the chances of early stopping were also higher at the third and fourth analyses 
(89.7% of early interruptions for crossing the lower boundary and 94.5% of interrup­
tions for crossing the upper boundary). The median HR of trials with results crossing 
the lower boundary ranged from 0.79 to 0.88, and on the average, the overestimate 
was 10.7%. For trials stopped because the upper boundary was crossed, the median 
HR ranged from 1.13 to 1.29, with an underestimate of effect equal to 19%.
The adoption of triangular test would have conducted, instead, to 95.3% of early 
interruptions (87.8% at upper boundary and only 7.5% at the lower boundary). The 
higher percentage of interruptions (64.8% of trials crossing the lower boundary and 
74.6% of trials crossing the upper boundary) occurred at the second and third analy­
ses. Also in this case, there was a convergence of the median HR towards the “real” 
effect: the median HR of trials with results crossing the lower boundary ranged from 
0.70 to 0.87, and on the average, the overestimate was 13.6%. For trials stopped
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because the upper boundary was crossed, the median HR ranged from 0.93 to 1.16, 
with an average underestimate of effect equal to 3.7%.
Table 4.10 reports the results of the simulation using eight looks.
W ith the naive method, the overall chance of early stopping was 24.2%: 20.0% 
of the trials crossed the lower boundary. The larger proportion of trials outside 
the boundary was observed in the first 4 looks (64.3% of trials crossing the lower 
boundary and 84.0% of trials crossing the upper boundary, occurred in these four 
earlier analyses). The median HR of trials with results crossing the lower boundary 
ranged from 0.70 to 0.89, and on the average, the overestimate was 16.1%. For trials 
stopped because the upper boundary was crossed, the median HR ranged from 1.12 
to 1.43, with an underestimate of effect equal to 35.7%.
For the alpha-spending function the percentage of early stopping was 9.6% (0.4% 
at upper boundary and 9.2% at the lower boundary, respectively) and the chances 
of early stopping were higher after the fourth analysis (82.6% of early interruptions 
for crossing the lower boundary, and 92.7% of interruptions for crossing the upper 
boundary). The median HR of trials with results crossing the lower boundary ranged 
from 0.57 to 0.88, and on the average, the overestimate was 11.4%. For trials stopped 
because results crossed the upper boundary, the median HR ranged from 1.13 to 1.40, 
with an underestimate of effect equal to 21.7%.
For the restricted procedure, the percentage of early stopping was 9.1% (0.5% 
at upper boundary and 8.6% at the lower boundary) and again the chances of early 
stopping were higher after the fourth analysis (93.3% of early interruption for crossing 
the lower boundary, and 74.5% of interruptions for crossing the upper boundary). The 
median HR of trials with results crossing the lower boundary ranged from 0.71 to 
0.88, and on the average, the overestimate was 11.4%. For trials stopped because 
the upper boundary was crossed, the median HR ranged from 1.13 to 1.62, with an 
underestimate of effect equal to 21.9%.
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W ith the triangular test 94.0% of trials interrupted early (87.0% a t upper boun­
dary, but only 7.0% at the lower boundary). Again, the higher percentage of inter­
ruptions (71.1% of trials crossing the lower boundary and 75.9% of trials crossing the 
upper boundary) occurred between the third and sixth analysis. The median HR of 
trials with results crossing the lower boundary ranged from 0.53 to 0.87, and on the 
average, the overestimate was 14.3%. For trials stopped because results crossed the 
upper boundary, the median HR ranged from 0.92 to  1.56, with an underestimate of 
effect equal to 4.4%.
4 .1 .1 .1  F req u en tis t ap p ro ach es
Table 4.1L: A n a ysis w ith o u t a d ju s tm e n t for m u ltip le  te s ts
N D a te P ts E ven ts
O b ta in ed S to p p in g  b o u n d a ry
z-value p-value z-value p -va lue
1 28/09/1997 1577 323 +0.56790 0.28505 ±1.96000 0.02500
2 15/10/1998 2069 643 +2.04657 0.02033 ±1.96000 0.02500
3 17/12/1999 2074 965 +1.75946 0.03926 ±1.96000 0.02500
4 05/09/2003 2074 1286 +0.60437 0.27279 ±1.96000 0.02500
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Tab] e 4.2: A lpha-spending function w it i  O’B rien and Flem ing boundaries
O btained Stopping boundary
N z-value p-value z-value p-value
1 +0.56790 0.28505 ±4.33263 0.00001
2 +2.04657 0.02033 ±2.96311 0.00152
3 +1.75946 0.03926 ±2.35902 0.00916
4 +0.60437 0.27279 ±2.01406 0.02200
45
3 0 -
1 5 -
- 1 5 -
-30  -
-45
72 145 219 292
Figure 4.1: A lpha-spending function w ith  O’B rien and F lem ing boundaries
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Table 4.3: T rian g u la r te s t
O b ta in ed
S to p p in g  b o u n d a ry
U p p e r Low er
N z-value p-value z-value p-value z-value p-value
1 +0.56874 0.28477 +2.95100 0.00158 -0.98111 0.16327
2 +2.04979 0.02019 +2.42652 0.00762 +0.37193 0.35497
3 +1.76041 0.03917 +2.26268 0.01183 +1.17727 0.11954
4 +0.60784 0.27165 +2.20930 0.01358 +1.76454 0.03882
Z
150 250 350200 300 400 450
-1 0
-2 0
-3 0
Figure 4.2: T rian g u la r te s t
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Table 4.4: R est r id ,ed procedure
O btained Stopping boundary
N z-value p-value z-value p-value
1 +0.56874 0.28477 ±4.00620 0.00003
2 +2.04979 0.02019 ±2.81635 0.00243
3 +1.76041 0.03917 ±2.28897 0.01104
4 +0.60784 0.27165 ±1.98305 0.02368
  i _i
2QD
-10
-30
Figure 4.3: R estricted  procedure
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Table 4.5: Hazard ratios (95% CIs) at stu d y  closure
M ethod A nalysis num ber H R  (95% C l)
SSD - 0.965 (0.860-1.083)
Naive 2 0.839 (0.709-0.993)
OBF 4 0.965 (0.895-1.081)
Triangular test 4 0.946 (0.847-1.081)
Restricted procedure 4 0.965 (0.860-1.082)
For the restricted procedure the median unbiased estimate of the HR and its 95% Cl 
have been calculated
4.1.1.2 Bayesian approach
At two-year the overall survival for the experimental group was assumed to be surve =  
0.57, whereas for the control group survc =  0.50. Using the notation of sections 1.2.3 
and 3.1.1, it follows that:
In {HRX) =  In [ln(0.57)/ln(0.50)] =  -0.210
corresponding to a HR of 0.81.
Therefore ascep =  |ln(iTR1)/1.6445| =  0.1281 e Np =  4.5/0.12812 =  274 subjects. 
In order to calculate Np, it has been taken into account the unbalancement in the 
randomization ratio (1 experimental: 2 control), using the formula Np =  ( .(r.+U2A:\
\  ° s c e p  /
where r  is the randomization ratio.
The following prior, likelihood and posterior distributions have been calculated:
- Uninformative prior expressed as iV[ln(l),oo];
- Sceptical prior ~  i\T[ln(l), 0.016];
- Enthusiastic prior ~  iV[ln(0.81), 0.016].
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Table 4.6: Likelihood and posterior distributions
N Likelihood U  ninform ative Sceptical Enthusiastic
1 N[ln(0.934), .014] N[In(0.934), .014] N[ln(0.964), .008] N[ln(0.875), .008]
2 N[ln(0.839), .007] N[ln(0.839), .007] N[ln(0.884), .005] N[ln(0.830), .005]
3 N[ln(0.886), .005] N[ln(0.886), .005] N[ln(0.910), .004] N[ln(0.869), .004]
4 N[ln(0.965), .003] N[ln(0.965), .003] N[ln(0.971), .003] N[ln(0.936), .003]
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Table 4.7: Probabilities o f  im provem ent greater than:
Target
im provem ent
Hazard
R atio N U ninform ative Sceptical E nthusiastic
0.00 1.00 1 0.719 0.665 0.938
2 0.982 0.961 0.996
3 0.962 0.941 0.990
4 0.727 0.708 0.892
0.025 0.93 1 0.484 0.339 0.758
2 0.890 0.763 0.947
3 0.759 0.638 0.870
4 0.264 0.208 0.451
0.05 0.86 1 0.250 0.101 0.435
2 0.629 0.361 0.707
3 0.347 0.187 0.453
4 0.029 0.014 0.064
0.07 0.81 1 0.116 0.023 0.191
2 0.342 0.109 0.369
3 0.098 0.028 0.127
4 0.002 0.000 0.004
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Table 4.8: H azard ratios and their 95% crec ibility  intervals
N Uninform ative Sceptical Enthusiastic
1 0.934 [0.741-1.177] 0.964 [0.813-1.143] 0.875 [0.738-1.037]
2 0.839 [0.712-0.988] 0.884 [0.771-1.014] 0.830 [0.724-0.952]
3 0.886 [0.775-1.013] 0.910 [0.809-1.024] 0.869 [0.772-0.977]
4 0.965 [0.859-1.084] 0.971 [0.874-1.079] 0.936 [0.842-1.040]
4.1 .1 .3  Sim ulations
The following values have been used:
- underlying HR: 0.965;
- daily event rate in the control arm: 0.00094887;
- accrual duration time: 3.69884 years;
- total study duration: 7.66872 years.
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4.1.2 IC O N  4/A G O -O V A R  2.2 Trial
Tables 4.11, 4.12, 4.13 and 4.14 report the results of naive method, alpha-spending 
function with OBF boundaries, triangular test, and the restricted procedure, respec­
tively. Plot of results of these analyses are also reported in Figures 4.4, 4.5, 4.6.
Table 4.15 summarises the estimates (HRs and 95% CIs) obtained at study closure, 
considered as the first crossed boundary or the last scheduled analysis, according to 
the results of each considered method.
Tables 4.16, 4.17 and 4.18 report the results obtained adopting Bayesian approach.
The naive method would have conducted to early stopping at the second analysis 
(HR=0.74; 95% Cl: 0.58-0.94; p<0.01, one sided), with an absolute overestimate of 
9%.
The other methods would have conducted to anticipated closure at the third 
analysis, with an overestimate of 6.3% for alpha spending function approach, and of 
4.5% for the other approaches. Bayesian approach showed that under the sceptical 
prior the overestimate at second look is 4%. The probability of an effect size larger 
than null is 98% at the second look, the probability of an effect size larger than 2.5% 
is 92%, while the probability of obtaining at least 5% reduction in mortality is 76%, 
suggesting that the benefit may be relevant. At the end of the study, the probability 
of some effect is high even under the sceptical prior (97%), and the chance to have 
a clinically relevant effect (say at least 5% reduction in mortality) is 54% under the 
sceptical and 77% under the enthusiastic priors.
Table 4.19 reports the results of the simulation with four looks.
Using the naive method, the overall chance of early stopping was 63.2%: 62.9% of 
the trials crossed the lower boundary, indicating an effect in favour of experimental 
arm. Again the larger proportion of trials outside the boundaries was observed in 
the first and second looks (57% of trials crossing the lower boundary and 96% of
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trials crossing the upper boundary). The median HR of trials with results crossing 
the lower boundary ranged from 0.66 to 0.82, and on the average, the overestimate 
was 10.4%. For trials stopped because the upper boundary was crossed, the median 
HR ranged from 1.19 to 1.45, with an underestimate of effect equal to 70.3%.
For alpha-spending function the percentage of early stopping was 55.6% (all at 
the lower boundary) and the chances of early stopping at the third or fourth analyses 
were 87.4%. The median HR of trials with results crossing the lower boundary ranged 
from 0.53 to 0.87, and on the average, the overestimate was 7.6%.
As for the restricted procedure, the percentage of early stopping was 54.5% (all 
at the lower boundary) and the chances of early stopping were also higher after the 
second analysis (84.3%). The median HR of trials with results crossing the lower 
boundary ranged from 0.49 to 0.81, and on the average, the overestimate was 7.8%.
The triangular test produced 86.6% of early interruptions (38.3% at upper boun­
dary and only 48.3% at the lower boundary). The higher percentage of interruptions 
(66.8% of trials crossing the lower boundary and 57.0% of trials crossing the upper 
boundary) occurred at the second and third analyses. The median HR of trials with 
results crossing the lower boundary ranged from 0.57 to 0.80, and on the average, 
the overestimate was 10.1%. For trials stopped because results crossed the upper 
boundary, the median HR ranged from 0.88 to 1.24, with an underestimate of effect 
equal to 14.1%.
Table 4.20 reports the results of the simulation using 8 looks.
With the naive method, the overall chance of early stopping was 63.3%: of those 
99.0% at the lower boundary. Again, the larger proportion of trials outside the 
boundary was observed in the first 4 looks (61.8% of trials crossing the lower boundary 
and 98.5% of trials crossing the upper boundary). The median HR of trials with 
results crossing the lower boundary ranged from 0.56 to 0.83, and on the average, 
the overestimate was 13.1%. For trials stopped because results crossed the upper
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boundary, the median HR ranged from 1.20 to 1.72, with an underestimate of effect 
equal to 97.7%.
For alpha-spending function the percentage of early stopping was 53.0% (all at the 
lower boundary) and the chances of early stopping were higher at the final analyses 
(88.0% of early interruption for crossing the lower boundary occurred after the fourth 
analysis). The median HR of trials with results crossing the lower boundary ranged 
from 0.44 to 0.82, and on the average, the overestimate was 8.4%.
For restricted procedure the percentage of early stopping was 52.5% (all at the 
lower boundary) and the chances of early stopping were higher after the fourth analy­
sis (87.0% of early interruption for crossing the lower boundary). The median HR of 
trials with results crossing the lower boundary decreased from 0.46 to 0.82, and on 
the average, the overestimate was 8.6%.
W ith the triangular test 86.5% of trials interrupted early (47.1% at the lower - 
boundary). The higher percentage of interruptions (65.2% of trials crossing the lower 
boundary and 65.4% of trials crossing the upper boundary) occurred between the 
third and sixth analysis. The median HR of trials with results crossing the lower 
boundary ranged from 0.34 to 0.81, and the overestimate was 11.0%. For trials 
stopped because the upper boundary was crossed, the median HR ranged from 0.88 
to 2.04, with an underestimate of effect equal to 15.7%.
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4.1.2.1 Frequentist approaches
Table 4.11: A nalysis w it lou t adjustm ent for m ultiple tests
N D ate P ts Events
O btained Stopping boundary
z-value p-value z-value p-value
1 18/05/1999 409 133 +1.84183 0.03272 ±1.96000 0.02500
2 09/10/2000 607 264 +2.43969 0.00735 ±1.96000 0.02500
3 19/11/2001 772 398 +2.60082 0.00467 ±1.96000 0.02500
4 26/03/2003 802 530 +2.10033 0.01784 ±1.96000 0.02500
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Table 4.12: A lp h a -sp en d in g  fu n c tio n  w ith  O ’B rien  an d  F lem ing  b o u n d a rie s
N
O b ta in ed S to p p in g  b o u n d a ry
z-value p-value z-value p-value
1 +1.84183 0.03272 ±4.33263 0.00001
2 +2.43969 0.00735 ±2.96311 0.00152
3 +2.60082 0.00467 ±2.35902 0.00916
4 +2.10033 0.01784 ±2.01406 0.02200
45
30
15  -
-15  -
-30 -
-45
33 •35 131
Figure 4.4: A lp h a-sp en d in g  fu n c tio n  w ith  O ’B rien  an d  F lem in g  b o u n d a rie s
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Table 4.13: T rian g u la r te s t
O b ta in ed
S to p p in g  b o u n d a ry
U p p e r Low er
N z-value p-value z-value p-value z-value p-value
1 +1.84873 0.03225 +2.96346 0.00152 -1.00314 0.15790
2 +2.45129 0.00712 +2.45536 0.00704 +0.29749 0.38305
3 +2.60389 0.00461 +2.27815 0.01136 +1.10438 0.13471
4 +2.09855 0.01793 +2.22153 0.01316 +1.67725 0.04675
100 2C0150
Figure 4.5: T rian g u la r te s t
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Table 4.14: R es tric ted  p ro c e d u re
N
O b ta in ed S to p p in g  b o u n d a ry
z-value p-value z-value p-value
1 +1.84873 0.03225 ±4.00908 0.00003
2 +2.45129 0.00712 ±2.86073 0.00211
3 +2.60389 0.00461 ±2.32252 0.01010
4 +2.09855 0.01793 ±2.01899 0.02174
10D
-20
-30
Figure 4.6: R e s tr ic te d  p ro c e d u re
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Table 4.15: H a za rd  ra tio s  (95%  C Is) a t  s tu d y  c losu re
M ethods A nalysis num ber H R  (95% C l)
SSD - 0.833 (0.702-0.988)
Naive 2 0.739 (0.579-0.942)
OBF 3 0.770 (0.634-0.942)
Triangular test 3 0.788 (0.628-0.968)
Restricted procedure 3 0.788 (0.637-0.952)
4.1 .2 .2  B ayesian  ap p ro ach
At two-year the overall survival for the experimental group was assumed to be surve =  
0.61, whereas for the control group survc — 0.50. It follows that:
In (HIh)  =  ln[ln(0.61)/ln(0.50)] =  -0.342
corresponding to a HR of 0.71.
Therefore ascep — |ln(iTR1)/1.6445| =  0.208 e Np — 4/0.2082 =  92 subjects. The 
following prior, likelihood and posterior distributions have been calculated:
- Uninformative prior expressed as iV[ln(l), oo];
- Sceptical prior ~  A [ln(l), 0.043];
- Enthusiastic prior ~  7V[ln(0.71), 0.043].
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Table 4.16: L ikelihood an d  p o s te r io r  d is trib u tio n s
N Likelihood U  n in fo rm ative Scep tical E n th u sia s tic
1 N[ln(0.723), .030] N[ln(0.723), .030] N[ln(0.826), .018] N[ln(0.718), .018]
2 N[ln(0.739), .015] N[ln(0.739), .015] N[ln(0.799), .011] N[ln(0.731), .011]
3 N[ln(0.769), .010] N[ln(0.769), .010] N[ln(0.808), .008] N[ln(0.758), .008]
4 N[ln(0.833), .008] N[In(0.833), .008] N[ln(0.856), .006] N[ln(0.814), .006]
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Table 4.17: Probabilities o f im provem ent greater than
Target
im provem ent
Hazard
R atio N U  ninform at ive Sceptical Enthusiastic
0.00 1.00 1 0.969 0.925 0.994
2 0.993 0.983 0.998
3 0.996 0.991 0.999
4 0.982 0.974 0.995
0.025 0.93 1 0.926 0.813 0.974
2 0.969 0.923 0.988
3 0.971 0.940 0.988
4 0.897 0.849 0.952
0.05 0.86 1 0.845 0.628 0.916
2 0.895 0.764 0.940
3 0.874 0.765 0.925
4 0.656 0.538 0.767
0.11 0.71 1 0.468 0.136 0.481
2 0.386 0.141 0.406
3 0.226 0.083 0.252
4 0.037 0.011 0.050
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Table 4.18: H a za rd  ra tio s  a n d  th e ir  95%  c red ib ility  in te rv a ls
N U n in fo rm ativ e S cep tical E n th u s ia s tic
1 0.723 [0.515-1.016] 0.826 [0.636-1.072] 0.718 [0.553-0.932]
2 0.739 [0.581-0.941] 0.799 [0.649-0.984] 0.731 [0.594-0.900]
3 0.769 [0.632-0.936] 0.808 [0.677-0.964] 0.758 [0.635-0.904]
4 0.833 [0.703-0.988] 0.856 [0.731-1.002] 0.814 [0.695-0.952]
4.1.2.3 S im ulations
The following values have been used:
- underlying HR: 0.833;
- daily event rate in the control arm: 0.000949;
- accrual duration time: 6.19576 years;
- total study duration: 6.85558 years.
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4.1.3 GIVIO-SITAC 01 Trial
Tables 4.21, 4.22, 4.23 and 4.24 report the results of naive method, alpha-spending 
function with OBF boundaries, triangular test, and the restricted procedure, respec­
tively. Plot of results of these analyses are also reported in Figures 4.7, 4.8, 4.9.
Table 4.25 summarises the estimates (HRs and 95% CIs) obtained at study closure, 
considered as the first crossed boundary or the last scheduled analysis, according to 
the results of each considered method.
All these methods would have allowed to reach a statistically significant result at 
the fourth analysis.
Tables 4.26, 4.27 and 4.28 report the results obtained adopting Bayesian approach.
Bayesian approach showed that under the sceptical prior, the probability of an 
effect size larger than zero is 98% at the fourth look, the probability of an effect size 
larger than 2.5% is 87%, while the probability to obtain at least 5% reduction in 
mortality is 53%, supporting the evidence of a moderate effect.
Table 4.29 reports the results of the simulation with four looks.
Using the naive method, the overall chance of early stopping was 74.0%: 73.9% 
crossed the lower boundary. The larger proportion of trials outside the boundaries 
was observed in the first and second look (61% of trials crossing the lower boundary 
and 100% of trials crossing the upper boundary occurred in these two analyses). The 
median HR of trials with results crossing the lower boundary ranged from 0.56 to 
0.76, and on the average, the overestimate was 11.2%. For trials stopped because 
the upper boundary was crossed, the median HR ranged from 1.44 to 1.71, with an 
underestimate of effect equal to 125.3%.
For alpha-spending function the percentage of early stopping was 66.5% (all oc­
curring at the lower boundary) and the chances of early stopping at the third or 
fourth analyses were 82.9%. The median HR of trials with results crossing the lower
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boundary ranged from 0.33 to 0.75, and on the average, the overestimate was 7.9%.
For the restricted procedure, the percentage of early stopping was 66% (all at 
the lower boundary) and the chances of early stopping were also higher at the third 
and fourth analysis: 79.7%. The median HR of trials with results crossing the lower 
boundary ranged from 0.36 to 0.75, and on the average, the overestimate was 8.4%.
W ith the triangular test 87.6% of early interruptions would have been observed 
(27.3% at upper boundary and 60.3% at the lower boundary). The higher percentage 
of interruptions (63.5% of trials crossing the lower boundary and 67.4% of trials 
crossing the upper boundary) occurred at the second and third analyses. The median 
HR of trials with results crossing the lower boundary ranged from 0.45 to 0.74, and on 
the average, the overestimate was 11.6%. For trials stopped because results crossed 
the upper boundary, the median HR ranged from 0.84 to 1.35, with an underestimate 
of effect equal to 23.2%.
Table 4.30 reports the results of the simulation using eight looks.
W ith the naive method, the overall chance of early stopping is 75.9%: 75.6% 
crossed the lower boundary. The larger proportion of trials outside the boundaries 
was observed in the first 4 looks (65.4% of trials crossing the lower boundary and 100% 
of trials crossing the upper boundary). The median HR of trials with results crossing 
the lower boundary ranged from 0.45 to 0.78, and on the average, the overestimate 
was 14.7%. For trials stopped because the upper boundary was crossed, the median 
HR ranged from 1.64 to 2.02, with an underestimate of effect equal to 164.4%.
For alpha-spending function the percentage of early stopping was 65.7% (all at 
the lower boundary) and the chances of early stopping were higher after the fourth 
analysis (82.5% of early interruptions). The median HR of trials with results crossing 
the lower boundary ranged from 0.34 to 0.76, and on the average, the overestimate 
was 9.6%.
For the restricted procedure, the percentage of early stopping was 64.8% (only one
X-
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trial crossed the upper boundary) and the chances of early stopping were also higher 
at the final analyses (81.8% of early interruption for crossing the lower boundary 
occurred after the fourth analysis). The median HR of trials with results crossing 
the lower boundary ranged from 0.35 to  0.76, and on the average, the overestimate 
was 9.5%. The trial who stopped a t the upper boundary had a  median HR equal to 
1.65, with an underestimate of 120.9%.
W ith the triangular test 89.1% of trials interrupted early (60.9% a t upper bound­
ary and 28.2% at the lower boundary). The higher percentage of interruptions (68.4% 
of trials crossing the lower boundary and 69.9% of trials crossing the upper bound­
ary) occurred between the fourth and seventh analyses. The median HR of trials with 
results crossing the lower boundary ranged from 0.20 to 0.75, and on the average, 
the overestimate was 12.7%. For trials stopped because results crossed the upper 
boundary, the median HR ranged from 0.83 to  2.86, with an underestimate of effect 
equal to 46.1%.
4.1.3.1 F req u en tis t ap p ro ach es
Table 4.21: A nalysis  w it lo u t a d ju s tm e n t fo r m u ltip le  te s ts
N D a te P ts E ven ts
O b ta in ed S to p p in g  b o u n d a ry
z-value p -value z-value p -va lue
1 15/11/1991 840 70 +1.59104 0.05582 ±1.96000 0.02500
2 31/12/1992 869 140 +1.80292 0.03572 ±1.96000 0.02500
3 24/01/1994 869 210 +1.75359 0.03976 ±1.96000 0.02500
4 04/09/1996 869 279 +2.40664 0.00804 ±1.96000 0.02500
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Tab!e 4.22: A lpha-spending function w ith  O ’Brien and F lem ing boundaries
O btained Stopping boundary
N z-value p-value z-value p-value
1 +1.59104 0.05582 ±4.33263 0.00001
2 +1.80292 0.03571 ±2.96311 0.00152
3 +1.75359 0.03976 ±2.35902 0.00916
4 +2.40664 0.03976 ±2.01406 0.02200
30  •
1 5 -
- 1 5 -
- 3 0 -
-45
35 70
Figure 4.7: A lpha-spending function w ith  O’Brien and F lem ing boundaries
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Table 4.23: T rian g u la r te s t
O b ta in ed
S to p p in g  b o u n d a ry
U p p e r Lower
N z-value p-value z-value p-value z-value p-value
1 +1.60044 0.05475 +2.95701 0.00155 -0.99176 0.16066
2 +1.80926 0.03521 +2.43572 0.00743 +0.34745 0.36413
3 +1.75761 0.03941 +2.27292 0.01152 +1.13655 0.12786
4 +2.41566 0.00785 +2.21703 0.01331 +1.71313 0.04334
7
-ID
-15
Figure 4.8: T rian g u la r te s t
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Table 4.24: R estricted  procedure
N
O btained Stopping boundary
z-value p-value z-value p-value
1 +1.60044 0.05475 ±4.03311 0.00003
2 +1.80924 0.03521 ±2.84670 0.00221
3 +1.75511 0.03962 ±2.32402 0.01006
4 +2.18473 0.01446 ±2.01827 0.02178
15
1D
&
5
Figure 4.9: R estricted  procedure
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Table 4.25: Hazard ratios (95% CIs) at stud y closure
M ethods A nalysis num ber H R  (95% C l)
SSD - 0.747 (0.590-0.947)
Naive 4 0.747 (0.590-0.947)
OBF 4 0.747 (0.596-0.969)
Triangular test 4 0.760 (0.575-0.990)
Restricted procedure 4 0.768 (0.593-0.968)
4.1.3.2 Bayesian approach
After five years the overall survival for the experimental group was assumed to be 
surve =  0.78, whereas for the control group survc =  0.70. It follows that:
In (Hlh)  =  In [ln(0.70)/ln(0.78)] =  -0.355
corresponding to a HR of 0.70.
Therefore ascep — |ln(iTRi)/1.6445| =  0.216 e Np =  4/(0.208)2 =  86 subjects. The 
following prior, likelihood and posterior distributions have been calculated:
- Uninformative prior expressed as 7V[ln(l), oo];
- Sceptical prior ~  iV[ln(l), 0.047];
- Enthusiastic prior ~  A[ln(0.70), 0.047].
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Table 4.26 Likelihood and posterior distribui dons
N Likelihood U ninform ative Sceptical Enthusiastic
1 N[ln(0.679), .057] N[ln(0.679), .057] N[ln(.840), .026] N[ln(.691), .026]
2 N[ln(0.735), .029] N[ln(0.735), .029] N[ln(,826), .018] N[ln(.722), .018]
3 N[ln(0.784), .019] N[ln(0.784), .019] N[ln(.841), .014] N[ln(.759), .014]
4 N[ln(0.747), .014] N[ln(0.747), .014] N[ln(.800), .011] N[ln(.736), .011]
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Table 4.27: Probabilities o f im provem ent greater than
Target
im provem ent
Hazard
R atio N U  ninform at ive Sceptical Enthusiastic
0.00 1.00 1 0.947 0.861 0.989
2 0.966 0.924 0.993
3 0.961 0.931 0.991
4 0.993 0.984 0.998
0.025 0.90 1 0.882 0.670 0.952
2 0.887 0.744 0.952
3 0.844 0.724 0.931
4 0.942 0.874 0.974
0.05 0.81 1 0.764 0.399 0.833
2 0.709 0.428 0.798
3 0.581 0.358 0.699
4 0.740 0.532 0.809
0.08 0.70 1 0.543 0.121 0.520
2 0.375 0.100 0.394
3 0.196 0.052 0.230
4 0.279 0.093 0.300
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Table 4.28: Hazard ratios and their 95% credibility intervals
N U ninform ative Sceptical Enthusiastic
1 0.679 [0.425-1.085] 0.840 [0.614-1.150] 0.691 [0.505-0.946]
2 0.735 [0.528-1.024] 0.826 [0.636-1.072] 0.722 [0.556-0.937]
3 0.784 [0.598-1.028] 0.841 [0.670-1.057] 0.759 [0.604-0.953]
4 0.747 [0.591-0.944] 0.800 [0.652-0.982] 0.736 [0.600-0.903]
4 .1.3.3 Sim ulations
The following values where used:
- underlying HR: 0.747;
- daily event rate in the control arm: 0.0001953;
- accrual duration time: 2.99247 years;
- total study duration: 7.43874 years.
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4.1 .4  Sum m ary of results
Table 4.31 reports the summary of the main results of the simulations: the more used 
statistical approaches reduce the risk of “incorrect” early stopping, compared with 
the adoption of no stopping rule.
Figures 4.10, 4.11, 4.12, show the estimated HRs and the relative unadjusted 95% 
CIs as a function of the percent of the total number of events observed during the 
course of the three studies considered: as expected the fluctuation is very high at the 
beginning of the study, but estimates are more stable after about half of information 
fraction is achieved.
It is therefore important to stress the fact tha t alpha-spending function and re­
stricted procedures allow early termination at the end of the study, favouring a re­
duction in the magnitude of estimation bias.
On the contrary naive method is more prone to lead to a termination at early 
stages, with a higher estimation bias.
Triangular test performs well regarding overestimation, but the more relaxed cri­
teria for stopping for futility, increase the study probability of an early termination 
concluding for no effect difference. Even in “positive” trials, the chance of stopping 
for futility are 39% in ICON 4 and 28.2% in GIVIO-SITAC 01 study.
It is also important to note that the chance of early stopping due to an overesti­
mate is directly related to the “true” magnitude of effect; the inverse is true in case 
of stopping for futility.
The number of analyses has a moderate impact on estimation, when a specific 
approach has been adopted, but it is important when no criteria for controlling for 
multiple analyses are used.
Ta
ble
 
4.
31
: 
Si
m
ul
at
io
n 
re
su
lt 
su
m
m
ar
y
R esults 95
Ei
gh
t 
an
al
ys
es
Bi
as
 
si
ze
 
re
la
te
d 
to 
st
op
16
.1
%
35
.7
%
11
.4
%
21
.7
%
14
.3
%
4.
4%
11
.4
%
21
.9
%
13
.1
%
97
.7
%
8.
4%
11
.0
%
15
.7
% S? 1CO
00
Ea
rly
 
st
op
 
gr
ea
te
st
 
ra
te
lo
ok
s 
1
-2
-3
-4
 
64
.3
%
 
84
.0
%
lo
ok
s 
5
-6
-7
-8
 
82
.6
%
 
92
.7
%
lo
ok
s 
3
-4
-5
-6
 
71
.1
%
 
75
.9
%
lo
ok
s 
5
-6
-7
-8
 
93
.3
%
 
74
.5
%
lo
ok
s 
1
-2
-3
-4
 
61
.8
%
 
95
.2
%
lo
ok
s 
5
-6
-7
-8
 
88
.0
%
lo
ok
s 
3
-4
-5
-6
 
65
.2
%
 
65
.4
%
lo
ok
s 
5
-6
—
7
-8
 
87
.0
%
Ra
te
 
of
 
ea
rly
 
st
op
s
24
.2
%
20
.0
%
4.
2%
9.
6%
9.
2%
0.
4%
94
.0
%
7.
0%
87
.0
%
9.
1%
8.
6%
0.
5%
63
.3
%
62
.7
%
0.
6%
53
.0
%
53
.0
%
86
.5
%
47
.1
%
39
.4
%
52
.5
%
52
.5
%
Fo
ur
 
an
al
ys
es
Bi
as
 
si
ze
 
re
la
te
d 
to 
st
op
13
.6
%
27
.0
%
10
.9
%
19
.0
%
13
.6
%
3.
7%
10
.7
%
19
.0
%
10
.4
%
70
.3
%
7.
6%
10
.1
%
14
.1
%
7.
3%
Ea
rly
 
st
op
 
gr
ea
te
st
 
ra
te
lo
ok
s 
1
-2
 
58
.0
%
 
77
.0
%
lo
ok
s 
3
-4
 
93
.4
%
 
96
.5
%
lo
ok
s 
2
-3
 
64
.8
%
 
74
.6
%
lo
ok
s 
3
-4
 
89
.7
%
 
94
.5
%
lo
ok
s 
1
-2
 
57
.0
%
 
96
.0
%
lo
ok
s 
3
-4
 
87
.4
%
lo
ok
s 
2
-3
 
66
.8
%
 
57
.0
%
lo
ok
s 
3
-4
 
84
.3
%
Ra
te
 
of
 
ea
rly
 
st
op
s
17
.2
%
14
.9
%
2.
3%
9.
5%
8.
9%
0.
6%
95
.3
%
7.
5%
87
.8
%
10
.6
%
9.
9%
0.
7%
63
.2
%
62
.9
%
0.
3%
55
.6
%
55
.6
%
85
.6
%
48
.3
%
38
.3
%
54
.5
%
54
.5
%
A
pp
ro
ac
h
N
ai
ve
- 
o
v
er
es
ti
m
a
te
- 
u
n
d
er
es
ti
m
a
te
O
B
F
- 
o
v
er
es
ti
m
a
te
- 
u
n
d
er
es
ti
m
a
te
T
ri
an
gu
la
r
- 
o
v
er
es
ti
m
a
te
- 
u
n
d
er
es
ti
m
a
te
R
es
tr
ic
te
d
- 
o
v
er
es
ti
m
a
te
- 
u
n
d
er
es
ti
m
a
te
N
a’
iv
e
- 
o
v
er
es
ti
m
a
te
-  
u
n
d
er
es
ti
m
a
te
O
B
F
- 
o
v
er
es
ti
m
a
te
- 
u
n
d
er
es
ti
m
a
te
T
ri
an
gu
la
r
- 
o
v
er
es
ti
m
a
te
- 
u
n
d
er
es
ti
m
a
te
R
es
tr
ic
te
d
- 
o
v
er
es
ti
m
a
te
- 
u
n
d
er
es
ti
m
a
te
S
tu
dy
IC
O
N
 
3 
HR
 
0.
96
5
IC
O
N
 
4 
HR
 
0.
83
3
co
nt
.
co
nt
., 
Ta
ble
 
4.
31
R esults 96
E
ig
h
t 
a
n
a
ly
se
s
B
ia
s 
si
z
e
 
re
la
te
d
 
to 
st
o
p
14
.7
%
16
4.
4%
9.
6%
12
.7
%
46
.1
%
9.
5%
E
ar
ly
 
st
o
p
 
g
re
a
te
st
 
r
a
te
lo
ok
s 
1
-2
-3
-4
 
65
.4
%
 
10
0.
0%
lo
ok
s 
5
-6
-7
-8
 
82
.5
%
lo
ok
s 
4
-5
-6
-7
 
68
.4
%
 
69
.9
%
lo
ok
s 
5
-6
-7
-8
 
81
.8
%
R
at
e 
o
f 
ea
rl
y 
st
o
p
s
75
.9
%
75
.6
%
0.
3%
65
.7
%
65
.7
%
89
.1
%
60
.9
%
28
.2
%
64
.8
%
64
.8
%
F
ou
r 
a
n
a
ly
se
s
B
ia
s 
si
z
e
 
re
la
te
d
 
to 
st
o
p
11
.2
%
12
5.
3%
7.
9%
11
.6
%
23
.2
%
8.
4%
E
ar
ly
 
st
o
p
 
g
re
a
te
st
 
r
a
te
lo
ok
s 
1
-2
 
61
.0
%
 
10
0.
0%
lo
ok
s 
3
-4
 
82
.9
%
lo
ok
s 
2
-3
 
63
.5
%
 
67
.4
%
lo
ok
s 
3
-4
 
79
.7
%
R
at
e 
o
f 
ea
rl
y 
st
o
p
s
74
.0
%
73
.9
%
0.
1%
66
.5
%
66
.5
%
87
.6
%
60
.3
%
27
.3
%
66
.0
%
66
.0
%
A
p
p
r
o
a
c
h
N
a'
iv
e
- 
o
v
er
es
ti
m
a
te
- 
u
n
d
er
es
ti
m
a
te
O
B
F
- 
o
v
er
es
ti
m
a
te
- 
u
n
d
er
es
ti
m
a
te
T
ri
an
gu
la
r
- 
o
v
er
es
ti
m
a
te
- 
u
n
d
er
es
ti
m
a
te
R
es
tr
ic
te
d
- 
o
v
er
es
ti
m
a
te
- 
u
n
d
er
es
ti
m
a
te
S
tu
d
y
SI
T
A
C
 
01
 
HR
 
0
.7
4
7
R esults 97
2.0
o
T3ura
NHJX
1.0
Information fraction (% )
0.0 J
0 25 50 75 100
Figure 4.10: IC O N  3 T rial - T ren d  over tim e  of th e  h a za rd  ra tio  e s tim a te  
(d a rk  b lue) a n d  its  lower an d  u p p e r  95% C l b o u n d s (b lue)
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Figure 4.11: ICO N  4/A G O -O V A R  2.2 Trial - Trend over tim e o f th e hazard
ratio estim ate (dark blue) and its lower and upper 95% C l bounds (blue)
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Figure 4.12: G IV IO /S IT A C  01 T rial - T ren d  over tim e  o f th e  h a z a rd  ra tio  
e s tim a te  (d a rk  b lue) an d  its  low er a n d  u p p e r  95% C l b o u n d s  (b lue)
Tables 4.32, 4.33 and 4.34 reports the values of the normal standardized statistic 
corresponding to the stopping rules, with 4 equally spaced analyses and overall type 
I error 0.05, for the three considered studies. The graphical plot of same data are 
presented in Figures 4.13, 4.14 and 4.15, in which for triangular test, only the levels 
corresponding to the upper boundaries are showed.
Although there is no formal need to present stopping boundaries within the 
Bayesian approach, the criterion such as “stop if posterior probability that the treat­
ment is beneficial is greater than 97.5%” has been also investigated and results under 
the sceptical prior are reported as well.
Achieved results are in line with what expected by the different approaches adopted:
for alpha-spending function and restricted procedure the boundaries are very similar,
while for triangular test and the Bayesian approach the boundaries are more relaxed
R esults 99
at the beginning, but a little bit stringent at the end of the study.
As far as Bayesian approach is concerned, it assures a protection similar to the 
triangular test, and although simulations have not been performed, it seems reasona­
ble to consider that the performance of Bayesian method is similar to what achieved 
using the triangular test.
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Table 4.32: IC O N  3 T rial - V alues o f th e  n o rm al s ta n d a rd iz e d  s ta t is tic  
co rre sp o n d in g  to  s to p p in g  ru les  in case o f four analyses ______________
N N aive O B F
T rian g u lar
te s t
R e s tr ic te d
p ro ced u re
S cep tical
p rio r
1 ±1.9600 ±4.33263 ±2.95100 ±4.00620 ±2.66461
2 ±1.9600 ±2.96311 ±2.42652 ±2.81635 ±2.34060
3 ±1.9600 ±2.35902 ±2.26268 ±2.28897 ±2.22085
4 ±1.9600 ±2.01406 ±2.20930 ±1.98305 ±2.15869
For triangular test only the levels corresponding to the upper boundaries are reported
4.5
- • -N a iv e
-B -O E F
-•-T ria n g iJa r  te s t  
Restricted p ro c ed re  
Bayes_____________
3. 5 -
2.5
1.5
50%
Inform ation  fraction
Figure 4.13: ICO N  3 Trial - Values o f th e norm al standardized sta tistic
corresponding to  stopping rules in case o f four analyses
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Table 4.33: IC O N  4 /A G O -O V A R  2.2 - V alues o f th e  n o rm a l s tan d a rd iz e d  
s ta tis tic  co rre sp o n d in g  to  s to p p in g  ru les  in  case o f four analyses_________
N N aive O B F
T rian g u lar
te s t
R e s tr ic te d
p ro ced u re
S cep tical
p rio r
1 ±1.9600 ±4.33263 ±2.96346 ±4.00908 ±2.54926
2 ±1.9600 ±2.96311 ±2.45536 ±2.86073 ±2.27599
3 ±1.9600 ±2.35902 ±2.27815 ±2.32252 ±2.17473
4 ±1.9600 ±2.01406 ±2.22153 ±1.01899 ±2.12327
For triangular test only the levels corresponding to the upper boundaries are reported
4.5
Naive 
—B-O'EF
-■ -T riangular te s t 
Restricted proee& re 
Bayes_____________
3.5 -
2.5 f
1.5
Inform ation  fraction
Figure 4.14: ICO N  4/A G O -O V A R  2.2 Trial - Values o f th e norm al stan­
dardized statistic  corresponding to  stopping rules in case o f four analyses
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Table 4.34: G IV IO /S IT A C  01 T rial - V alues o f th e  n o rm a l s tan d a rd iz e d  
s ta tis tic  co rre sp o n d in g  to  s to p p in g  ru les  in  case o f four analyses_________
N N aive O B F
T rian g u lar
te s t
R e s tr ic te d
p ro ced u re
Scep tical
p rio r
1 ±1.9600 ±4.33263 ±2.95701 ±4.03311 ±2.92591
2 ±1.9600 ±2.96311 ±2.43572 ±2.84670 ±2.49022
3 ±1.9600 ±2.35902 ±2.27292 ±2.32402 ±2.32694
4 ±1.9600 ±2.01406 ±2.07325 ±1.01827 ±2.24178
For triangular test only the levels corresponding to the upper boundaries are reported
4.5
-a-OBF
-B -T riangular te s t
Restricted proce& re 
Bayes_____________
3.5
2 .5-
1.5
Info rm ation  fraction
Figure 4.15: G IV IO /SIT A C  01 Trial - Values o f the norm al standardized
statistic  corresponding to  stopping rules in case o f four analyses
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4.2 Early reports in scientific literature
As showed in Figure 4.16, according to the research strategy, a subgroup of 1495 out 
of 12347 (12%) cancer phase III RCT papers was identified and manually checked 
in order to pick up the relevant publications, i.e. early reports of therapy trials in 
oncology.
A vast majority of papers was not relevant for the research, since the choice of 
using generic terms, such as “early” or “preliminary” increased sensitivity, but at the 
same time reduced specificity. In fact, “early” is seldom related to the preliminary 
nature of the publication; rather, it is mainly used for referring to stage of disease or 
to results obtained in similar previous researches. Likewise, the term “preliminary” 
is often referred to phase I-II clinical trials.
After the initial manual screening, 178 papers were considered in details: 83 were 
found to be eligible for the analysis.
10852 
not relevant
PubMied search
83
eligible
Figure 4.16: Search  flow d iag ram
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Table 4.35 reports the reasons for publication by year. Sixtyfour out of the 83 
RCTs (77%) were interim analyses related to efficacy, while 19 were articles aimed at 
describing either patient population characteristics or results not related to efficacy 
endpoints.
We will mainly focus on interim analysis reports on efficacy.
Table 4.35: R easons for p u b lica tio n  by y ear
P u b lica tio n  reason
In te rim  analysis
E arly  re su lts  
no efficacy All
N % N % N %
Y ear
2000 14 87.5 2 12.5 16 19.3
2001 8 66.7 4 33.3 12 14.5
2002 17 81.0 4 19.0 21 25.3
2003 17 77.3 5 22.7 22 26.5
2004 6 60.0 4 40.0 10 12.0
2005 2 100.0 2 2.4
All 64 77.1 19 22.9 83 100
Studies were performed particularly on breast, lung and haematological neo­
plasms, and the most investigated treatment was chemotherapy (43 out of 64 trials, 
67%). These data are shown in Tables 4.36, 4.37 and 4.38.
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Table 4.36: D isease localisa tion
D isease localisation N %
Breast 12 18.8
Lung 12 18.8
Haematological 9 14.1
Colorectal 5 7.8
Gastric 4 6.3
Prostate 4 6.3
Genital 4 6.3
Urological 3 4.7
CNS 3 4.7
Head & neck 2 3.1
Pancreatic 2 3.1
Esophageal 2 3.1
Melanoma 1 1.6
GIST 1 1.6
All 64 100
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Table 4.37: In v es tig a ted  tre a tm e n t
In v es tig a ted  tre a tm e n t N %
Chemotherapy 43 67.2
Ormonotherapy 7 10.9
Radiotherapy 7 10.9
Surgery 4 6.3
Radiotherapy+chemotherapy 3 4.7
All 64 100
Table 4.38: D isease localisation  an d  in v estiga ted  tre a tm e n t
D isease localisa tion In v estig a ted  tre a tm e n t N %
B reas t 12 18.8
Chemotherapy 7 58.8
Ormonotherapy 4 33.3
Surgery 1 8.3
L ung 12 18.8
Chemotherapy 12 100.0
H aem ato log ical 9 14.1
Chemotherapy 8 88.9
Surgery 1 11.1
C olorectal 5 7.8
Chemotherapy 4 80.0
Radiotherapy+chemotherapy 1 20.0
cont.
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cont., Table 4.38
D isease localisation In v es tig a ted  tre a tm e n t N %
G astric 4 6.3
Chemotherapy 3 75.0
Surgery 1 25.0
P ro s ta te 4 6.3
Ormonotherapy 2 50.0
Radiotherapy 2 50.0
G en ita l 4 6.3
Chemotherapy 3 75.0
Surgery 1 25.0
U rological 3 4.7
Chemotherapy 2 66.7
Ormonotherapy 1 33.3
CNS 3 4.7
Radiotherapy 2 66.7
Radiotherapy-hormonotherapy 1 33.3
H ead  &; neck 2 3.1
Radiotherapy 2 100.0
P an c rea tic 2 3.1
Chemotherapy 2 100.0
E sophageal 2 3.1
Radiotherapy 1 50.0
Radiotherapy+chemotherapy 1 50.0
cont.
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cont., Table 4.38
D isease localisation In v es tig a ted  tre a tm e n t N %
M elanom a 1 1.6
Chemotherapy 1 100.0
G IS T 1 1.6
Chemotherapy 1 100.0
The results of the trials were published mainly on specialized journals, but even 
when published on general journals, the impact factor was always high, as shown in 
Table 4.39.
Table 4.39: T ype  o f jo u rn a l an d  im]pact fac to r
T yp e  of jo u rn a l Im p ac t F ac to r N %
IN T E R IM  ANALYSIS
Specialized < 2 19 29.7
< 4 14 21.9
> 4 25 39.1
G enera l > 4 6 9.4
All 64 100
EA R LY  RESU LTS
Specialized < 2 8 42.1
< 4 5 26.3
> 4 6 31.6
All 19 100
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Choice of publication on journals with higher impact factor is associated with the 
presence of a DSMC and the decision of stopping the trial early, based on the results 
obtained by the interim analysis (Tables 4.40 and 4.41).
Table 4.40: T yp e  of jo u rn a l an d  im p ac t fac to r (n = 6 4 )
Im p ac t fac to r
N M edian M ean SD
T Y P E  O F JO U R N A L
Specialized 58 3.605 4.846 4.014
General 6 34.833 32.080 6.743
T R IA L  S T O P P E D ?
No 27 2.381 3.548 3.454
Yes 37 6.511 10.209 10.770
D SM C
No 51 3.605 5.555 7.064
Yes 13 10.864 14.635 12.346
S T O P P IN G  RU LES
No 29 2.381 3.563 3.749
Yes 35 6.511 10.577 10.853
SA M PL E  SIZE
<100 5 1.159 3.095 4.566
<250 24 2.459 6.004 9.456
<500 22 7.799 7.436 4.568
>500 13 3.772 11.568 13.468
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Table 4.41: A ssocia tion  b e tw een  h igher im p ac t fac to r w ith  decision o f s to p ­
p ing  an d  D SM C  p resence  (n = 6 4 )
Variable D F
Parameter
estimate
Standard
error t-value p-value
Intercept 1 3.29 1.567 2.096 0.0402
Trial stopped? (yes/no) 1 4.63 2.199 2.105 0.0395
DSMC (yes/no) 1 7.08 2.699 2.622 0.0110
In 29 (45%) of the trials no formal approach of stopping rules was described.
Bayesian approach was never used, since in the remaining 35 papers a frequentist 
method was adopted, even if in 20 cases (57.1%) without the specification of the 
chosen type.
The presence of a DSMC was reported in 13 out of 64 (20%) studies, all in 
publications of trials using some form of specified approach of interim analysis. DSMC 
is more reported in trials of medium-large dimensions, i.e. with a number of expected 
patients greater than 250.
All these data are reported in Tables 4.42 and 4.43.
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Table 4.42: P resen ce  of s to p p in g  ru les an d  o f a  D SM C
P resen ce T ype N %
S T O P P IN G  RU LES
N o 29 45.3
Yes 35 54.7
Frequentist, unspecified 20 58.8
Frequentist, o-spending OBF 6 17.6
Frequentist, OBF 4 11.8
Frequentist, o-spending OBF+CP 1 2.9
Frequentist, Peto+CP 1 2.9
Frequentist, restricted procedure 1 2.9
Frequentist, Pocock 1 2.9
Frequentist, CP 1 2.9
D SM C
N o 51 79.7
Presence of stopping rules 29 56.9
Absence of stopping rules 22 43.1
Yes 13 20.3
Presence of stopping rules 13 100
All 64 100
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Table 4.43: P resen ce  of s to p p in g  ru les  an d  ex p ec ted  sam ple  size (n = 6 4 )
S topp ing  ru les D SM C
Sam ple N o Yes No Yes
size N % N % N % N %
<100 4 13.8 1 2.9 4 7.8 1 7.7
<250 15 51.7 9 25.7 22 43.1 2 15.4
<500 7 24.1 15 42.9 17 33.3 5 38.5
>500 3 10.3 10 28.6 8 15.7 5 38.5
The effect of interim analysis results on continuation of the trial are showed in 
Table 4.44.
In four papers, the trials were stopped for reasons other than efficacy or futility, 
i.e. for an accrual lower than expected or lack of resources. In 27 out of 64 papers 
the study was continued. Stopping for efficacy reasons was reported in 24 papers, 
while in 9 cases the study was reported to have been stopped for futility.
Interestingly, in those papers not mentioning any form of policy for interim analy­
ses, the studies continued in 20 (69%) out of 29, while in papers reporting some form 
of policy, only 7 (20%) trials continued and the remaining 35 were stopped early. The 
principal reason for stopping was efficacy, accounting for 24 studies (37.5%); the ratio 
between reason for stopping (effficacy/futility) was 2.7:1, not associated to reporting 
of policy presence.
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Table 4.44: D ecision ta k en  based  on in te rim  analysis re su lts  (n = 6 4 )
S topp ing
rules
C on tinued
S to p p ed
efficacy
S to p p ed
fu tility
S to p p ed
o th e r
N % N % N % N %
No 20 69.0 5 17.2 2 6.9 2 6.9
Yes 7 20.0 19 54.3 7 20.0 2 5.7
All 27 42.2 24 37.5 9 14.1 4 6.2
In 36 (56%) studies the early report was drawn while the study accrual was still 
ongoing, in 19 out of 36 the study was interrupted for efficacy and in 6 out of 36 for 
futility. Instead, only in 9 out of 28 (32%) studies in which analysis was performed 
after the end of the accrual, the trial was stopped (Table 4.45).
The relationship among the decision of interrupting the study (and therefore of 
producing an early publication) and the presence of a policy of stopping rules, the 
presence of a DSMC and the trial size was assessed by means a logistic regression 
model, whose results are reported in Table 4.46. They suggest that, when a trial is 
stopped, the probability of publishing the results of an interim analysis is increased 
in presence of specific stopping rules.
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Table 4.46: R ela tio n sh ip  am ong  of p ro b ab ility  o f early  p u b lica tio n  an d  s tu d y  
ch arac te ris tic s___________  .
V ariab le
P o in t
e s tim a te
95% W ald  
confidence in tervals
DSMC (yes:no) 7.170 0.504 101.923
Stopping rules (yes:no) 6.566 1.832 23.533
Sample size 0.888 0.702 1.124
4.3 U se of interim analyses in randomized onco­
logical trials
According to the research strategy, a subgroup of 836 cancer protocols was identified 
and manually checked in order to pick up the relevant trials.
Figure 4.17 reports the flow of the selection of relevant protocols: 143 (17.1%) 
out of 836 protocols were eligible and evaluable for analysis. 128 (15.3%) investigated 
outcomes different from time to event, such as pain control, 406 (48.6%) were single 
arm trials, 64 (7.7%) considered a time to event endpoint only as secondary outcome 
measure. Ninetyfive (11.4%) studies at the moment of the analysis were not yet fully 
included in the registry, since their protocol was not available.
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341
759
prctocol net yetavail able
: 418 not eligible - 
since not randomized
77 net eligible 
since nob on anbtumoral drugs
103 net eligible 
since primary endpoint not a 
time to event
Figure 4.17: Search  flow d iag ram
Comparison of the 143 fully eligible and evaluable protocols with the 95 eligible 
but not yet evaluable trials (Table 4.47) shows tha t not evaluable studies are less 
recent, since mostly evaluated before 2002 (68.4% compared to 23.1% in evaluable 
trials, x 2=:5 7 .9 ,  5 df, p<  0.0001), launched generally only in Italy (46.0% vs. 25.2%, 
X2=10.4, 2 df, p=0.0054), more often of phase II (22.1% vs. 7.0%, x 2=10.1, 2 df, 
p=0.012) and preferentially conducted by no profit organisations (x2=T4.04, 1 df,
p=0.0002).
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Table 4.47: C om parison  b e tw een  evalua Die an d  n o t evaluable  tr ia ls
N o t evaluable E valuab le
N % N %
Y E A R
2000 36 37.9 13 9.1
2001 29 30.5 20 14.0
2002 13 13.7 19 13.3
2003 10 10.5 31 21.7
2004 4 4.2 38 26.6
2005 3 3.2 22 15.4
S P O N S O R
No profit 56 59.0 46 32.2
Profit 39 41.0 97 67.8
P H A S E
II 21 22.1 10 7.0
III 72 75.8 132 92.3
IV 2 2.1 1 0.7
IN V O LV ED  C O U N T R IE S
Italy 35 46.0 36 25.2
Europe 1 1.3 9 6.3
Worlwide 40 52.6 98 68.5
not specified 19
All 95 143
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Tables from 4.48 to 4.53 report the characteristics concerning disease localisation, 
the investigated treatment and the clinical setting of the 143 evaluable studies.
The large majority of the studies are to be conducted on solid tumors (85.3%), 
and the more frequently investigated diseases are lung (37, 25.9%) and breast cancers 
(30, 21.0%).
Chemotherapy is the preferred investigated strategy, accounting for 103 (72%) of 
the protocols, while ormonotherapy with or without chemotherapy is tested in 14 
studies, 11 out of the 30 (36.7%) breast cancer protocols and all of the 3 protocols 
on advanced prostate cancer.
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Table 4.48: D isease localisa tion  (n= 143)
D isease localisa tion N %
Solid
Lung 37 25.9
Breast 30 21.0
Colorectal 10 7.0
Head Sz Neck 7 4.9
Urogenital 7 4.9
Gynaecological 6 4.2
Melanoma 5 3.5
Pancreas 4 2.8
Liver 3 2.1
Prostate 3 2.1
Gastric 3 2.1
Sarcoma 2 1.4
Adrenocortical 1 0.7
Biliary 1 0.7
Brain 1 0.7
GIST 1 0.7
Anal 1 0.7
H aem ato log ical 21 14.7
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Table 4.49: In v es tig a ted  tre a tm e n t
In v es tig a ted  tre a tm e n t N %
Chemotherapy 103 72.0
Chemotherapy+radiotherapy 10 7.0
Ormonotherapy 7 4.9
Chemotherapy+ormonotherapy 7 4.9
Immunotherapy 6 4.2
Chemotherapy+immunotherapy 5 3.5
Other 3 2.1
Chemotherapy+other 2 1.4
All 143 100
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Table 4.50: C lin ical se ttin g
T um or C linical se ttin g N %
Solid 122 85.3
Early- 23 18.9
Adjuvant 19 82.6
Neoadjuvant 4 17.4
Advanced 99 81.2
Locally advanced 55 55.5
Metastatic 26 26.3
Both 18 18.2
H aem ato log ical 21 14.7
Adult 19 90.5
Pediatric 2 9.5
A ll 143 100
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Table 4.51: C lin ical s e ttin g  an d  tu m o r localisa tion  (on ly  fo r  so lid  tu m o rs )
D isease localisa tion S e ttin g N %
Lung 37
Early 3 8.1
Advanced 34 91.9
B reas t 30
Early 8 26.7
Advanced 22 73.3
C olorectal 10
Early 4 40.0
Advanced 6 60.0
U rogen ita l 7
Early 2 28.6
Advanced 5 71.4
H ead  &: neck 7
Advanced 7 100.0
G ynaecological 6
Advanced 6 100.0
M elanom a 5
Early 1 20.0
Advanced 4 80.0
P an creas 4
Advanced 4 100.0
Liver 3
Early 1 33.3
Advanced 2 66.7
cont.
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cont., Table 4.51
D isease localisation S e ttin g N %
P ro s ta te 3
Advanced 3 100.0
G astric 3
Early 3 100.0
Sarcom a 2
Early 1 50.0
Advanced 1 50.0
A nal 1
Advanced 1 100.0
A dren o co rtica l 1
Advanced 1 100.0
B iliary 1
Advanced 1 100.0
B ra in 1
Advanced 1 100.0
G IS T 1
Advanced 1 100.0
All 122 100
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Table 4.52: T rea tm e n t an d  clinical se ttin g
T um or S e ttin g T rea tm en t N %
Solid 122 85.3
Early- 23 18.8
Chemotherapy 14 60.9
Ormonotherapy 4 17.4
Immunotherapy 3 13.0
Chemo+radiotherapy 1 4.4
Chemo+ormonotherapy 1 4.4
Advanced 99 81.2
Chemotherapy 72 72.3
Chemo+radiotherapy 8 8.1
Chemo+ormonotherapy 6 6.1
Chemo+immunotherapy 5 5.0
Ormonotherapy 3 3.0
Immunotherapy 3 3.0
Other 2 2.0
H aem ato log ical 21 14.7
Adult 19 90.5
Chemotherapy 15 79.0
Chemo+other 2 10.5
Chemo+radiotherapy 1 5.3
Other 4 5.3
Pediatric 2 9.5
Chemotherapy 2 100.0
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Table 4.53: D isease localisa tion  an d  inv estig a ted  tre a tm e n t (on ly  f o r  so lid  
tu m o rs  )
D isease localisa tion T rea tm en t N %
Lung 37
Chemotherapy 32 86.5
Chemo+radiotherapy 1 2.7
Immunotherapy 2 5.4
Chemo+immunotherapy 1 2.7
Other 1 2.7
B reas t 30
Chemotherapy 17 56.7
Chemo+radiotherapy 1 3.3
Chemo+ormonotherapy 6 20.0
Ormonotherapy 5 16.7
Other 1 3.3
C olorectal 10
Chemotherapy 8 80.0
Chemo+radiotherapy 1 10.0
Immunotherapy 6 10.0
U rogen ita l 7
Chemotherapy 5 71.4
Chemo+immunotherapy 2 28.6
H ead Sz neck 7
Chemotherapy 2 28.6
Chemo+radiotherapy 2 71.4
cont.
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cont., Table 4.53
D isease localisation T rea tm en t N %
G ynaecological 6
Chemotherapy 6 100.0
M elanom a 5
Chemotherapy 2 40.0
Immunotherapy 1 20.0
Chemo+immunotherapy 2 40.0
P an creas 4
Chemotherapy 4 100.0
Liver 3
Chemotherapy 2 33.3
Immunotherapy 2 66.7
P ro s ta te 3
Chemo+ormonotherapy 1 33.3
Ormonotherapy 2 66.7
G astric 3
Chemotherapy 3 100.0
S arcom a 2
Chemotherapy 2 100.0
A nal 1
Chemo+radiotherapy 1 100.0
A d ren o co rtica l 1
Chemotherapy 1 100.0
cont.
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cont., Table 4.53
D isease localisa tion T rea tm en t N %
B iliary 1
Chemotherapy 1 100.0
B ra in 1
Chemotherapy 1 100.0
G IS T 1
Chemotherapy 1 100.0
A ll 122 100
Table 4.54 describes the planned number of patients to randomize, of the events 
to observe toghether with the expected proportion of events at the end of the study, a 
good index of patient prognosis, calculated as the ratio of these two latter variables.
Table 4.55 shows the planned duration of the study, as well as those of the accrual 
and follow-up.
Table 4.54: P la n n e d  n u m b er o f p a tie n ts , even ts an d  ex p ec ted  p ro p o r tio n  o f 
events a t final analysis____________________________________________________
N M edian M ean SD M in M ax
N . of p a tie n ts 143 490.0 712.6 846.96 36 5800
N. of events 103 390.0 439.4 263.92 6 1280
E v e n ts /
p a tien ts 103 0.70 0.65 0.196 0.13 0.95
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Table 4.55: D u ra tio n  of th e  s tudy , accrua l an d  follow-up (m on ths)
N M edian M ean SD M in M ax
S tu d y  d u ra tio n 110 42.5 49.8 26.99 15.0 150.0
A ccrual 116 24.0 26.9 13.32 9.0 84.0
Follow-up 109 18.0 23.9 19.11 2.0 120.0
Table 4.56 reports a description of interim analyses, if planned, and the presence 
of a DSMC.
Interim analyses were planned in 92 (64.3%) of the protocols, while DSMC was 
reported in 83 (58.0%) out of the 143 evaluable protocols.
Table 4.56: P resen ce  of s to p p in g  ru les an d  o a  D SM C
N %
In te rim  analysis
No 51 35.7
Yes 92 64.3
D SM C
No 60 42.0
Yes 83 58.0
In te rim  analysis D SM C
■ No No 38 26.6
Yes 13 9.1
Yes No 22 15.4
Yes 70 49.0
All 143 100
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The median number of interim analyses was 1, ranging from 0 to 5 for efficacy, 
and from 0 to 15 for safety assessment, as reported in Table 4.57.
Table 4.57: N u m b er of in te rim  analyses for efficacy or safety
N M edian M ean SD M in M ax
For efficacy 92 1.0 1.3 0.88 0 5
For safety 90 0.0 0.7 1.98 0 15
Table 4.58 shows the main characteristics of the interim efficacy analyses, while 
Table 4.59 those of interim safety analyses.
Of note, among the 80 protocols reporting the objective of efficacy analysis, in 6 
(7.5%) cases the endpoint is related to activity, and therefore it is different from the 
main objective of the final analysis.
Interim analyses for efficacy were planned according to the proportion of observed 
events in 54 out of 80 evaluable protocols, according to the proportion of patients in 
20 protocols and based on calendar time in the remaining 6 protocols.
In the 22 trials reporting the planned timing strategy for safety analyses, they 
were generally based on patients proportion (14), on calendar time (4) or on the 
number of toxic events (4).
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Table 4.58: C h arac te ris tic s  of th e  in te rim  efficacy analyses
N %
O bjective
Not stated 12 13.0
Activity endpoint 6 6.5
Efficacy endpoint 72 78.5
Mixed endpoint 2 2.2
T im ing
No 14 15.2
Yes 78 84.8
T yp e  of tim in g
Not stated 12 13.0
Events 51 55.4
Patients 20 21.7
Calendar time 6 6.5
Patients and events 3 3.3
All 92 100
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Table 4.59: C h arac te ris tic s  o f th e  in te rim  safety  analyses
N %
O bjective
Not stated 67 72.8
Safety endpoint 25 27.2
T im ing
No 75 81.5
Yes 17 18.5
T y p e  of tim in g
Not stated 70 76.1
Events 4 4.3
Patients 14 15.2
Calendar time 4 4.3
All 92 100
The most frequent type of statistical approach for the analysis was the frequentist 
method, implementing the OBF boundaries (70 out of 92, 76.1%); conditional power 
was used in 3 studies, while Bayesian approach was taken into consideration only in 
one study, as shown in Table 4.60.
A DSMC was planned in 13 out of 51 protocols (25%) without a planned interim 
analysis, while it was not considered in 22 out of 72 protocols in which interim analysis 
was planned.
Overall, no form of monitoring was found in 38 out of 143 protocols (27%).
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Table 4.60: In te r im  analysis an d  presence  o D SM C
D SM C
p resen t
D SM C  
n o t p re sen t A ll
T yp e N % N % N %
Not planned 13 15.7 38 63.3 51 35.7
Freq, OBFa 53 63.9 17 28.3 70 49.0
Freq, Peto6 2 2.4 1 1.7 3 2.1
Freq, TTC 1 1.2 0 - 1 0.7
Freq, CPd 2 2.4 1 1.7 3 2.1
Freq, other 11 13.2 3 5.0 14 9.8
Bayesian 1 1.2 0 - 1 0.7
All 83 58.0 60 42.0 143 100
a Frequentist, Alpha-spending function with O’Brien and Fleming boundaries 
6 Frequentist, Peto approach 
c Frequentist, Triangular test 
d Frequentist, Conditional power
Table 4.61 shows that in 18 out of 83 protocols, the only commitment of DSMC 
was safety. Efficacy was considered in 65 protocols, but only in two it was the 
only commitment of DSMC, while in the remaining 63 the DSMC had the task of 
monitoring safety and efficacy. In one case, DSMC had also the task of deciding the 
timing and type of statistical analysis.
Composition and frequence of meetings for DSMC were reported only in 6 and 18 
protocols, respectively. Usually the DSMC was composed by 3 or 4 people, always 
with one statistician, and the frequency of the meetings was generally every 6 months 
or every year.
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Table 4.61: D SM C  task s
N %
Task
Efficacy 2 2.4
Safety 18 21.7
Efficacy+safety 62 74.7
Efficacy-f-safety+statistical analysis 1 1.2
N u m b er of D SM C  m eetings
Not defined 77 92.8
3 5 6.0
4 1 1.2
F requency  of D SM C  m eetings
Not defined 71 85.5
Every 6 months 8 9.6
Every 12 months 4 4.8
All 83 100
Table 4.62 shows the association among selected characteristics of the study pro­
tocols (type of sponsorship, international collaboration, year of submission) and the 
presence of both planned interim analyses and DSMC.
Although all these factors but year of submission show an association at univaria­
te analysis, at multivariate logistic analysis (Table 4.63) the most important factor 
associated with the presence of interim analysis or of DSMC is the international 
organization of the study, accounting for an odds ratio for the presence of DSMC of 
5.6 (95% Cl 2.2-14.2) and of 5.1 (95% Cl 1.9-13.1) for presence of a planned interim 
analysis.
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Table 4.62: A ssocia tion  am ong  s tu d y  p ro to co l ch arac te ris tic s  an d  p resence  
of in te rim  analysis an d  D SM C  (n= 143)
D SM C In te rim
N o Yes No Yes
N % N % N % N %
Sponsor
29 48.3 17 20.5 22 43.1 24 26.1No profit
Profit 31 51.7 66 79.5 29 56.9 68 73.9
In te rn a tio ­
nal s tu d y
33 55.0 12 14.5 27 52.9 18 19.6No
Yes 27 45.0 71 85.5 24 47.1 74 80.4
Y ear of 
subm ission
5 8.3 8 9.6 5 9.8 8 8.72000
2001 11 18.3 9 10.8 6 11.8 14 15.2
2002 11 18.3 8 9.6 8 15.7 11 12.0
2003 13 21.7 18 21.7 12 23.5 19 20.7
2004 11 18.3 27 32.5 12 23.5 26 28.3
2005 9 15.0 13 15.7 8 15.7 14 15.2
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Table 4.63: R ela tio n sh ip  betw een  presence  o f b o th  in te rim  analyses an d
D SM C  an d  selec ted  prolto col ch arac te ris tic s
V ariab le
P o in t
e s tim a te
95% W ald  
C l
O dds ra tio  e stim ates  for p resence  o f in te rim  analyses
Sponsor (profit/no profit) 0.857 0.331 2.214
International 
collaboration (yes/no) 5.106 1.988 13.114
Year of submission 0.969 0.763 1.231
O dds ra tio  e stim ates  for p resence  of D SM C
Sponsor (profit/no profit) 1.553 0.614 3.930
International 
collaboration (yes/no) 5.585 2.200 14.179
Year of submission 1.144 0.898 1.457
Chapter 5
Discussion
5.1 Statistical findings and m ethodological context
The most important findings of our research can be summarised as follows:
- the adoption of a statistical approach for data monitoring, no m atter of which 
type chosen, effectively protects from the risk of an incorrect early stopping;
- if no stopping rule is adopted, the probability of early stopping with a higher 
estimation bias is noticeably increased;
- performance of restricted procedure and alpha-spending function with OBF 
boundaries are very similar, while triangular test yields results which resemble 
those obtained by Bayesian approach. Triangular test performs well regarding 
over estimation, but the more relaxed criteria for stopping for futility increase 
the study probability of interruption, concluding for no difference between treat­
ments;
- the chance of early stopping due to an overestimate is directly related to the 
“true” magnitude of effect; the inverse holds for stopping for futility;
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- the number of analysis has a moderate impact on estimation, when some ap­
proach is adopted, but it is important when no criteria for controlling for mul­
tiple analyses are used.
- stabilization of the estimates appears to happen when a substantial amount 
of events has occurred. Therefore, it seems appropriate to conduct interim 
analyses only after about half of the expected events occurred, in order to reduce 
bias. W ith respect to this, alpha-spending function and restricted procedure 
are more protective against stopping at the beginning of the study, favouring a 
reduction in the magnitude of estimation bias.
These findings confirm previous research in the field (Pocock and Hughes, 1989; 
Korn et al., 2004) and stress the importance of adopting some form of statistical 
approach for data monitoring.
Our research, rather than finding differences, emphasizes the qualitative similarity 
of the various options, in that they all are conservative in protecting against an 
inappropriate early stopping of a trial.
Nevertheless, if bias can be reduced, it cannot be avoided, since at any particular 
interim analysis, clinical trials with an observed effect that is by chance greater than 
the true effect ( “random high”), are more likely to exceed the stopping boundaries 
than trials on a “random low” , especially if the true effect is relatively small.
Our research confirms on real-life data most of the components associated to the 
bias due to multiple looks and well described in the literature (Hughes and Pocock, 
1988), which can be summarised as follows:
- bias is higher when no sequential design is adopted; however, even when it is 
used, a distribution skewed toward overestimation of effect is observed;
- bias increases with the ease with which a trial can stop early;
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- the size of trial affects the results: smaller trials usually produce less extreme 
estimates than larger trials but, if they stop early, result in a more exaggerate 
estimation of treatment effect at corresponding stage;
- bias is more marked when the true risk ratio can be detected with a reasonable 
power;
- for moderate treatment effects the bias is increased for designs that allow early 
termination more readily;
- different frequencies of monitoring may have a moderate impact on biased es­
timation.
An other relevant issue is related to the impact on bias estimation of different 
frequencies of monitoring.
In agreement with this last statement, Freidlin et al. (1999) argued tha t in terms 
of protection level and power there is little reason not to monitor frequently the 
relative treatment efficacy, and frequent monitoring offers advantages in being able 
to end some trials earlier.
However, although the additional bias seems to be small, the size of the adjustment 
is dependent on the unknown true hazard ratio and there are no means of knowing 
whether the surprisingly large observed effect is true. Therefore it is always important 
to consider the possibility that chance has played a part in achieving the observed 
results.
The finding that estimation bias tends to be reduced when the observed number of 
events is closer to the planned size is particularly important for cancer clinical trials 
also for non-statistical reasons. W ith time to event endpoints, a potential problem 
with stopping a trial earlier is that the early experience with short follow-up may not 
reflect accurately the complete survival experience.
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A new treatment may be very toxic, leading to a few early deaths, but may also 
have much better long-term results than the standard treatment. Overall, the new 
treatment may be viewed as better than the standard, but the early look at the data 
may suggest stopping for lack of efficacy. The opposite is also possible, since early 
suggestions of treatment efficacy may decline over time. This problem can be lessened 
by deferring the formal interim monitoring.
One further factor that should be considered is the scientific and ethical relation­
ship that links the decision of stopping a trial early with its implication on ongoing 
trials, addressing the same clinical question, and on the chance that a confirmatory 
trial is planned. In either these situations, it is suggested that the issues of interpreta­
tion of observed effect (plausibility: unrealistically large results needed for stopping; 
precision: imprecision due to the small sample size in the early analyses) might be 
better faced in Bayesian context.
Recognition of requirement for large effects to stop the trial early leads to shrin­
kage methods to produce plausible estimates.
This results in a Bayesian approach, whereby the plausibility of different treatment 
effects is quantified beforehand. This quantification is of course subjective, but it is 
important to note that the classical specification of nominal significance for stopping 
is arbitrary, too and the choice among the various monitoring rules may also reflect 
prior opinion.
Bayesian approach has the advantage of emphasizing estimation rather than sig­
nificance testing, and the choice of prior can reflect the degree of expectation of 
genuine treatment differences. As an example, in tumors for which no or small pre­
vious advances in therapy have been made, the prior should be centred toward zero 
effect, thus requiring more data before apparent treatment effect would justify stop­
ping.
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5.2 Contribute of surveys on protocols and publi­
shed early reports
Analysis of protocols and early reports suggests that, although the field of methodo­
logy of interim analyses of clinical trials is largely covered and different approaches 
are available, the implementation of these procedures in a monitoring strategy is still 
scarce.
According to the sources of data investigated, analysis of statistical aspects of 
RCT protocols in oncology, systematically collected in the National Monitoring Cen­
tre for Clinical Trials, reveals that the most recent trend, based on the analysis of 
the international and national trials with participation of Italian centres, is not yet 
completely satisfactory.
The most important figures derived indicate tha t only sixty-four percent of the 
protocols incorporate statistical interim analysis plans. Despite of the large availabi­
lity of statistical methods for interim analysis, the almost uniquely approach is the 
frequentist method, with OBF boundaries.
DSMCs are present in 58% of protocols, but there is lack of information on their 
composition and on the rules to be implemented.
The only factor clearly associated to the adoption of planned interim analyses and 
to the presence of DSMC is the multinational participation to the study.
Some positive findings are that, in accordance to the characteristics of survival 
analysis, usually the timing is related to the number of events and almost half of the 
trials adopt not more than one planned interim analysis, thus reducing the risk of 
estimation bias.
When looking at the data derived from early reports, the adoption of a for­
mal process of interim analysis affects only a minority (13%) of published trials 
and slightly more than half (55%) of early publications based on interim analysis.
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Again, the largely preferred approach is the frequentist method, generally with OBF 
boundaries.
Explicit use of DSMC is reported only in 10% of published reports and in 20% 
of reports of early publication based on interim analyses, with lack of information 
regarding its rules and composition. DSMC presence is associated to the size of 
clinical trial.
Publication of early results on high impact factors journals is associated to the 
decision of stopping the trial early, based on the results obtained by the interim 
analysis and to the presence of a DSMC.
These data, together with the finding that the publication of trials interrupted 
due to the results of interim efficacy analysis are associated with planned stopping 
rules, suggest that access to the publication of early reports, particularly on highly 
referenced journals, may depend not only from the observed effect of the treatment 
but also from the reliability of monitoring process.
The findings related to interim analyses are not so dissimilar from those emerged 
from the Italian registry of clinical trial protocols, and are complementary to those 
published in the Health Technology Assessment (HTA) report on issues in data mo­
nitoring and interim analysis of trials (Grant et al., 2005).
In tha t report, it was shown that planned interim analysis was reported in 16% 
and presence of DSMC in 18% of randomised clinical trials published in selected 
general medical journal and specialist medical journals in 2000. Focusing on onco­
logy journals, these figures were even worse, since only 8% of trials reported DSMC 
presence in the same year.
Since our research strategy for selecting relevant papers is different from the ap­
proach used in the HTA report study, these results are not easily comparable.
We chose only papers reporting early publications from 2000 to 2005, while the 
survey of HTA focused on retrieving all the trials published in 1990 and 2000 on
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selected journals.
The reason of our choice was that we were particularly interested in picking up 
reports in which some mention on the form of interim analysis would have to be 
expected, thus overcoming the potential problem of underreporting in HTA analysis. 
Nevertheless, although the data may suggest some sort of improvement in reporting 
details of interim analysis, the data are still unsatisfactory, since even in this more 
favourable situation, 45% of reports did not mention any form of planned stopping 
rule.
Moreover, our data, particularly those derived from the protocol search, confirm 
the scarce attitude to provide details on the rules that a DSMC should adopt, on the 
relationship between study Steering Committee and DSMC, so reinforcing the im­
portance of recommending that explicit guidelines must be prepared for each DSMC 
prior to the start of the trial, specifying clearly how it will operate (Sydes et al., 2004).
5.3 Conclusions
The most important ’take-home’ message of our research is that interim analyses play 
a fundamental role in the balance between the need of timely information regarding 
the treatment effect and the control of false positive errors and estimation bias.
Since trials are often analysed before their planned end, it is absolutely necessary 
to implement statistical stopping rules in the context of the monitoring process, which 
should be performed by an appropriate DSMC.
The most discussed and popular approaches appear to have good performance.
However, the use of interim analyses is still limited basically to the OBF frequen­
tist approach, while the Bayesian method is not considered, although in the context of 
monitoring it would be more useful for its characteristics of flexibility in incorporating
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external evidence.
Interim analysis plan are still scarcely described, even in more recent protocols, 
denoting a not yet sufficient attention to this issues not only by the researchers, but 
also by the regulatory boards that should consider the ethical and scientific aspects 
of the submitted studies.
Also, the evidence of underreporting of statistical methods on journals, even when 
early reports based on results of interim analyses are published, can be considered as 
a further signal of the gap between methodological availability of statistical methods 
and their actual use.
These considerations induce some further thoughts relative to the discrepancy 
between the perceived importance of data monitoring boards and the scarcity of data 
regarding the description of their presence in clinical trials, their composition and 
their role.
It can be argued that the importance of adoption of a monitoring strategy is 
far more relevant than the choice of a particular type of statistical analysis. As a 
matter of facts, when monitoring clinical trials, many problems can face for a sort of 
different issues. For example, some of the most important problems may be related 
to the different endpoints chosen for interim analysis, whose relevance can also be 
different when compared to the time of analysis, or to the evidence of effects in 
selected subgroups of patients, but not in others (Ellenberg et et al., 2003).
Conflicting results on type of endpoint, chosen time (long term vs. early) and 
in subgroups of patients constitute perhaps the most important conceptual issue of 
clinical trials interpretation and they are even more problematic in interim analyses.
Conflicts in ethical and philosophical point of views also constitute other group of 
issues: some investigators argue that, at least for some trials, the objective should be 
to produce results that are persuasive enough to effect changes in medical practice 
(Liberati, 1994).
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In particular situation, such as in confirmatory pragmatic trials where researchers 
are more interested in effect estimation than in assessing the efficacy of the experi­
mental treatment, trial interruption may provoke an important loss of precision in 
the estimate of benefit or detriment associated to the treatment under investigation 
(Sohuami, 1994).
On the other hand, other investigators may not be keen to accept tha t a trial 
might be continued far longer than necessary to persuade most knowledgeable clinical 
researchers, requiring continue randomisation of participants to an inferior treatment.
Determining the optimal length of follow-up can be difficult in a clinical trial 
having an early beneficial trend. Ideally, evaluating the duration of treatm ent benefit 
while continuing to assess possible side-effects or toxicity over a longer period of time 
would provide the maximum information for clinical use.
However this solution is not always viable, since for patients with a life-threatening 
disease such as advanced cancer, evidence of short-term therapeutic benefits may be 
compelling even it is unknown whether these benefits are sustained over the longer 
term. It is also important to recognise the effect of early stopping on the complete 
pattern of knowledge which is expected from a trial: after the trial has been early 
closed, patients on the control arm may begin to receive the new beneficial treatm ent, 
comparisons of the study arms become less meaningful and evaluating long-term 
side-effects and whether benefit is sustained becomes more difficult. In these cases 
the choice of implementing interim analyses, and the weight of statistical results on 
the decision to stop the trial, can vary according to different clinical scenarios: for 
patients with a chronic disease the long-term effects of the therapy may be of greater 
importance in evaluating the benefit-to-risk ratio. In this case, a focus on longer- 
term outcomes may sometimes be justified even in the presence of a strong but 
short-term beneficial trend. When such diseases are progressive, however, there will 
inevitably be a conflict between the desire to prevent irreversible disease progression
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in as many patients as possible, and the desire to understand the long-term effects of 
the treatment, which should be solved on a “case by case” basis.
A further issue raises when an unexpected toxicity profile begins to emerge. In 
this case, the level of a safety concern that would lead to a recommendation for 
modification or termination of the study will necessarily vary with the level of benefit 
being observed. If the treatment appears to be offering a survival benefit, for example, 
a strong suggestion of a serious and unexpected safety problem might lead to some 
changes in the protocol to reduce the problem, while the same magnitude of safety 
concern might lead to a recommendation to terminate the study if the interim efficacy 
results were less promising.
For this reason when interim monitoring of comparative data is conducted to 
assess safety issues, efficacy data should also be reviewed in order to enable an in­
formed assessment of the benefit-to-risk profile. In some trials, no apparent trends of 
either beneficial or harmful effects emerge as the trial progresses toward its planned 
conclusion. In such instances, decision should take into account the investment in 
participants, physicians and resources, as well as the discomfort of the trial on pa­
tients.
All these examples illustrate the difficulties of the decisions tha t sometime have 
to be taken, when monitoring a clinical trial and the important effects such decisions 
may have. They make even more clearer how important is the role of DSMC and 
why interim analyses must be considered an important tool to be used as guideline 
for decision.
There are good examples in literature regarding the positive dialectic between the 
results of interim analysis and the decision of DSMC.
Wheatley and Clayton (2003) stated that the preliminary results of the twelfth 
Medical Research Council acute myeloid leukemia trial (Wheatley et al., 2002) showed 
no evidence of a survival advantage for five courses of therapy compared to four
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courses in a randomised comparison involving 1078 patients (HR 1.09, 95% Cl 0.87- 
1.37, p—0.4). However, the data presented to the DSMC at both its reviews in 1998 
suggested large benefits for the additional course with HRs of 0.47 and 0.55 (95% CIs 
0.29-0.77 and 0.38-0.80, p=0.003 and p=0.002, respectively).
Despite these highly significant findings, the DSMC did not recommend closure 
of the randomisation. In this example, the choice of fixed stopping rules based on 
p-value was questionable. According to Whitehead (2004), the best choice for this 
trial would have been a triangular test with asymmetric boundaries, since in this 
case experimental arm was more toxic and expensive than control arm. Using this 
approach, the study would have continued and terminated with a non-significant 
conclusion. However, the main reason for not closing the randomization was not 
related to the maybe inappropriate statistical method chosen for interim analysis, 
rather it was based on the consideration that the treatment effects observed early 
(53% and 45% reductions in the odds of death) were considered too large to be 
clinically plausible, despite the p-values associated with them.
Investigations did not identify any clinical explanation, such as different types of 
patients in the earlier and later parts of the trial, to explain the loss of benefit as 
the trial progressed. Thus, the most likely current explanation for the large benefit 
observed early on was the play of chance.
According to the authors, the following considerations have to be made: fixed 
stopping rules based simply on a rigid predefined p-value should never by employed 
in a trial to dictate when it should be stopped. Stopping rules should be recom­
mendations, nothing more, and need to be interpreted wisely. Other factors, both 
internal and external to the trial, should always be taken into account.
In this case, the internal factor tha t the treatment effect was implausibly large 
was given greater weight than the observed p-value. Thus, although the analyses were 
based on the traditional frequentist approach, their interpretation used an informal
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Bayesian approach, that took account of the prior beliefs and expectations that any 
benefit from adding a fifth course would be, at best, moderate.
Even more important, in our view, is the appropriate use of interim analyses, 
particularly when clinical study design and ultimate study question are in conflict 
with early evaluation of results. In these situations, the importance of DSMC to 
make the “right” choice is clearly pivotal.
The Letrozole study (Goss et al, 2003), a trial which had a considerable effect 
on the treatment of early-stage breast cancer, is very helpful as example to highlight 
these issues and therefore it will be described in details.
The study was led by the National Cancer Institute of Canada Clinical Trials 
Group and was a joint effort of the North American Intergroup and the Breast Inter­
national Group .
The rationale of the study was based on the fact that it is accepted that in 
hormone-dependent breast cancer, five years of postoperative tamoxifen therapy, but 
not tamoxifen therapy of longer duration, prolongs disease-free and overall survival. 
Since the aromatase inhibitor letrozole, by suppressing estrogen production, might 
improve the outcome after the discontinuation of tamoxifen therapy, this double­
blind, placebo-controlled trial was therefore conducted to test the effectiveness of 
five years of letrozole therapy in postmenopausal women with breast cancer who had 
completed five years of tamoxifen therapy. The primary end point was disease-free 
survival. A total of 5187 women were enrolled (median follow-up: 2.4 years).
At the first interim analysis, there were 207 local or metastatic recurrences of 
breast cancer or new primary cancers in the contralateral breast, 75 in the letrozole 
group and 132 in the placebo group, with estimated four-year DFS rates of 93 percent 
and 87 percent, respectively, in the two groups (p < 0.001 for the comparison of DFS).
A total of 42 women in the placebo group and 31 women in the letrozole group 
died (p=0.25 for the comparison of overall survival). Low-grade hot flashes, arthritis,
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arthralgia, and myalgia were more frequent in the letrozole group, while vaginal 
bleeding was less frequent. There were new diagnoses of osteoporosis in 5.8 percent 
of the women in the letrozole group and 4.5 percent of the women in the placebo 
group (p=0.07); the rates of fracture were similar.
After the first interim analysis, conducted using the Lan-DeMets alpha spending 
function with OBF boundaries, applied accordingly to what planned in the study pro­
tocol, the DSMC recommended termination of the trial and prompt communication 
of the results to the participants.
The decision, provoked a lot of reactions.
According to Bryant and Wolmark (2003), although the decision of early stopping 
seemed justifiable on statistical and ethical sides, on the other hand, the decision to 
close the study after a median follow-up of only 2.4 years, to inform all participants 
of the findings and the treatment they received, and to offer letrozole to the women 
who were originally assigned to placebo undeniably diminished the clinical usefulness 
of the data.
In addition, the relative reduction of 24 percent in the hazard of death from 
any cause in the letrozole group as compared with placebo group reduction was not 
statistically significant and it is possible that a survival advantage would never be 
documented, since ongoing follow-up is confounded by crossover. The findings cannot 
be useful for supporting recommendation of five years of letrozole treatm ent, since 
none of the participants have been followed up to five years, and follow-up for adverse 
events has been even shorter. It was also not possible to quantify the magnitude of a 
potential benefit with respect to disease free survival, not only because of the small 
number of events that have been reported to date, but also because of uncertainty 
about the interval for which the treatment benefit may persist.
The result had obvious implications also for concurrent trials: ongoing placebo- 
controlled trials of treatment with aromatase inhibitors after five years of tamoxifen
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therapy could be modified or terminated in response to the announcement of these 
study results.
Therefore, there was no opportunity to collect data from a placebo-controlled trial 
that would help to evaluate the risks of long-term adverse events.
As a consequence of all these issues, Bryant and Wolmark suggested tha t the 
DSMC should not generally stop a trial early except for reasons of safety, if doing so 
would compromise the primary aim of the trial. The same authors also suggested that 
the protocol document should specify a minimal level of follow-up to be completed 
before allowing early reporting if the reason for early reporting is efficacy and warned 
that this example showed that stopping rules are based on simplified models of reality 
and will never capture all elements of the decision-making process.
Difficulties may also arise when there is lack of proportionality of hazard, espe­
cially when the curves separate and then come together (a frequent event in non­
curative treatments) and also when there is an early detriment due to toxicity or 
other cause but a longer-term advantage so that the curves cross over.
The importance of DSMC appears more recognised in the recent research proto­
cols, but it is still insufficiently appreciated.
Promotion of guidelines for the structure and organisation of DSMC would be of 
great importance for improving both the effectiveness and efficiency of monitoring 
process.
For this reason, the DAMOCLES working party (Grant, 2005) addressed seve­
ral different issues, using different methodological approaches: systematic literature 
reviews of DSMC , small group processes in decision-making; sample surveys of: 
reports of RCTs, recently completed and still ongoing RCTs and policies of major 
organisations involved in RCTs; case studies of selected DSMCs; and interviews with 
experienced DSMC members.
The results of these studies clearly indicated that wide variation exists in the
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structure and organisation of DSMCs, with little guidance on how they should o- 
perate. The conclusions they reached were that data monitoring should always be 
considered, and, differently from what is the actual current trend, reasons should 
be given not for justifying the presence of a DSMC, but where there is no DSMC 
or when any member is not independent. They also gave some practical advise for 
optimising the function of DSMC: for example, they stressed the importance of early 
DSMC meetings and of the agreement with investigators before the study initiation 
on roles, responsibilities and planned operations. Independence of the members and 
declaration of absence of conflict of interests were also recognised as important cha­
racteristic of DSMC. Finally, the primary roles of DMCS were indicated: DSMC have 
to ensure tha t continuing a trial according to its protocol is ethical, taking account 
of both individual and collective ethics and, in order to properly operate, the DSMC 
should know in advance the range of recommendations or decisions open to it.
It was also suggested that final reports should be also commented by DSMC and 
should include information about the data monitoring process and details on DSMC 
membership. The findings aided the development of a template for a charter guide­
line for DSMCs, whose widespread use would promote a systematic and transparent 
approach, and enable them to operate more effectively and efficiently.
Our research is in complete syntony with these conclusions and clearly indicates 
that much has still to be done for helping in the decision on the kind of statistical 
analyses that should be implemented, on the contribute of the results of such analyses 
on the final decision to be taken, and on the role of DSMC.
In our view, our results are a further contribute to the knowledge on data monito­
ring approaches and are of help for the identification of the questions to be addressed 
by further researches for improving organisation and conduction of clinical trials. In 
this sense, the findings from survey of Italian protocols seem of particular interest: 
although we are aware that they may be valid particularly in Italian research context
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and not totally generalizable to other countries, we think that this research represents 
a good point for debating the issues on how to improve monitoring of clinical trials, 
underlines the importance of the adoption of national registries and encourages the 
replication of this kind of research, even in other countries were national registries of 
clinical trials are available.
Chapter 6
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SAS Macro routine
Version 
Author .... 
Date Created 
Project
Program ... : SIMULA.SAS
Scope .....  : Computing distribution of In(HR) at specific time
points 
1.0
Irene Floriani 
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Statistical approach to interim analysis: 
a critical appraisal 
Macros Used. :
Usage .....  :
 Example__
7,SIMULA (Nsample=10000,
N=2074,
tasso=0.00094887,
HR=0.965, 
recluta= 3.69884, 
finestudio= 7.66872, 
interim=323 643 965 1286, 
zu=l.96*1.96*1.96*1.96, 
zl=-l.96*-l.9 6 * - l.96*-l.96, 
output=phd.icon3_noadj)
\7oMACRO SIMULA
(NSAMPLE= /*Nr. of sample to be generated (dataset) */
,RECLUTA= /*Accrual Time (Years) */
,FINESTUDI0= /*Maximum nr. of years of follow-up */
,HR= /*Hazard Ratio Treated vs Control */
,N= /*Sample Size */
,TASS0= /*Daily Incidence Rate in Control Group */
/*(-log[S(t)]/t with t=n.ro days */
/*S(t) expected survival in control group */
/*at day t and exponential risk = costant */
/*time rate */
,INTERIM= /*Periods of Interim Analysis */
SAS M acro routine 166
,ZU= /*<Description Here> */
, ZL= /*<Description Here> */
,OUTPUT=PARMS /*Final Output Dataset */
/*(default=PARMS) */
) ;
°/0LET MACRO=SIMULA;
7.LET VERSI0N=1.0;
***Start Macro;
7,PUT (&MACR0 &VERSI0N) Begin;
***Local Macros;
7„D0 S=1 7,TO &NSAMPLE;
* . *
* *
* Sample Generation *
*  *
* ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ *
data sample&S(keep=time entra esce status treat sample); 
attrib
entra length=8 label="Entry Time"
treat length=8 label="Arm"
status length=8 label="Status"
time length=8 label="Time";
do i=l to &N;
/*uniform distribution from 0 to 365 days*/ 
entra=int(ranuni(-1)*(365*&RECLUTA))+1; 
/*treatment allocation*/ 
treat=ranbin(-l,1,0.5);
/*Hazard Ratio */
HR=&HR; 
beta=log(HR);
/*Daily Rate*/ 
lambda=(&tasso);
/*End of study*/ 
c=&FINESTUDI0*365; 
u=ranuni(-2);
/*Event Time*/
t=-log(u)/ (lambda*(exp(beta*treat)));
/*Time and Censoring*/ 
esce=min(int(entra+t),c); 
if esce<c then status=l; 
else status=0; 
time=esce-entra;
/*Sample*/ 
sample=&S; 
output;
end;
run;
proc sort data=sample&s;
by entra; 
run;
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*    -------------------------------------
*
* Interim analysis
*
* ---------------------------------------------------------------------------------------------------------------
°/,LET NSCAN=1;
°/,LET NEVENT=7«SCAN (&INTERIM, &NSCAN) ;
%D0 #/,WHILE (&NEVENT NE ) ;
'/.LET NSCAN=#/„EVAL(&NSCAN+1) ;
'/.LET NEVENT=°/0SCAN (&INTERIM, &NSCAN) ; 
e/,END;
°/,LET NPLAN=#/,EVAL(&NSCAN-1) ;
'/LET NSCAN=1 *
°/oLET NEVENT=°/oSCAN (&INTERIM, &NSCAN) ;
'/.DO “/.WHILE (&NEVENT NE ) ;
***Run intetim analysis; 
data sample&S&NSCAN; 
set sample&S; 
by entra;
retain nevent 0 stop 0; 
nevent=sum(nevent,status); 
if stop eq 0 then output;
if last.entra and nevent ge &NEVENT then stop=l;
run;
proc phreg data=sample&S&NSCAN outest=parms&S&NSCAN noprint;
model time*status(0)=treat; 
run;
***Test if beta>z or <-z;
#/,LET _ZU_=°/,SCAN(&ZU,&NSCAN, *) ;
°/,LET _ZL_=°/,SCAN(&ZL,&NSCAN, *) ; 
data parms&S&NSCAN; 
set parms&S&NSCAN; 
coffu=(&_ZU_*2)/sqrt(&NEVENT); 
coff1=(&_ZL_*2)/sqrt(&NEVENT); 
hr=exp(treat); 
hr_u=exp(coffu); 
hr_l=exp(coff1); 
if treat>coffu then stop=l; 
else if treat<coffl then stop=-l; 
else stop=0;
call symput(’stop’,abs(stop)); 
if stop=-l then stop=2; 
run;
%LET NSCAN=#/,EVAL(&NSCAN+1) ;
'/.LET NEVENT=°/oSCAN(&INTERIM,&NSCAN) ;
'/.IF &ST0P EQ 1 '/.THEN %LET NEVENT=;
°/,END;
***Dataset with all interim analysis Beta estimates;
°/„LET NINTERIM='/,EVAL (&NSCAN-1) ; 
data p&S; 
set
'/,D0 NEV=1 '/,T0 &NINTERIM;
parms&S&NEV(in=in&NEV)
°/0END;
°/„D0 NEV=1 '/.TO &NINTERIM;
* 
* 
* 
*
SAS Macro routine 168
if in&NEV then ninterim=&NEV;
7,END;
sample=&S; 
run;
7«END; #/,***D0 1=1 TO NSAMPLE;
***Set all estimates; 
data parms; 
set
7.D0 1=1 7.T0 &NSAMPLE;
P&I
°/„END;
9
if stop ne 0 then output; 
if (ninterim=&NPLAN) then do; 
ninterim=99999; 
stop=99999; 
output;
end;
run;
proc format;
value stop 2=’Estimated at Lower’
1=’Estimated at Upper’
99999=’Reached final analysis’;
value ninterim 99999=’Final’; 
run;
***Stats of all estimates;
proc means data=parms n min p5 plO median p90 p95 max 
nway maxdec=3 noprint; 
class stop ninterim; 
var hr;
format stop stop, ninterim ninterim.; 
label
stop = "Boundary" 
ninterim="Nr. Analysis"; 
output out=stats n=n min=min max=max
p5=p5 plO=plO p95=p95 p90=p90 median=median;
run;
data stats; 
set stats; 
tr=&HR;
array _stat_ (stat) min p5 plO median p90 p95 max n; 
_id_="&0UTPUT"; 
do stat=l to 8;
name=vname(_stat_); 
value=_stat_; 
output;
end;
run;
proc sort data=stats;
by tr _id_ stop stat name; 
run;
***Save Output Results;
proc transpose data=stats out=&OUTPUT(drop=_name_) prefix=stage; 
id ninterim;
by tr _id_ stop stat name;
var value; 
run;
data &0UTPUT;
length st age 1-st age0/oLEFT(&NPLAN) stagefinal 8; 
set &0UTPUT;
* 
* 
* 
* 
*
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staged St age’ ; 
run;
End of Macro
'/.GOTO TERM;
°/«QUIT:
°/,TERM:
***Clear the environment; 
proc sql noprint; 
drop table stats; 
drop table parms;
•/.DO 1=1 #/.T0 &NSAMPLE;
°/0STR(drop table sample&I;); 
‘/,STR(drop table P&I;) ;
•/.DO T=1 °/,T0 &NINTERIM;
‘/,str(drop table parms&I&T;); 
'/.str(drop table sample&I&T;); 
‘/.END;
‘/.END;
quit;
‘/.PUT (&MACRO&VERSION) Finish;
‘/.MEND SIMULA;
* 
* 
* 
*
